

UC San Diego

UC San Diego Previously Published Works

Title

Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries

Permalink

<https://escholarship.org/uc/item/6fn1m7tr>

Journal

Nature Communications, 12(1)

ISSN

2041-1723

Authors

Gharahkhani, Puya
Jorgenson, Eric
Hysi, Pirro
et al.

Publication Date

2021

DOI

10.1038/s41467-020-20851-4

Peer reviewed

Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries

Puya Gharakhani ^{1,190}✉, Eric Jorgenson ^{2,190}, Pirro Hysi ^{3,190}, Anthony P. Khawaja ^{4,5,190}, Sarah Pendergrass^{6,190}, Xikun Han ¹, Jue Sheng Ong ¹, Alex W. Hewitt ^{7,8}, Ayyellet V. Segre⁹, John M. Rouhana ⁹, Andrew R. Hamel⁹, Robert P. Igo Jr ¹⁰, Helene Choquet ², Ayub Qassim¹¹, Navya S. Josyula ¹², Jessica N. Cooke Bailey ^{10,13}, Pieter W. M. Bonnemaier ^{14,15,16}, Adriana Iglesias ^{14,15,17}, Owen M. Siggs ¹¹, Terri L. Young ¹⁸, Veronique Vitart ¹⁹, Alberta A. H. J. Thiadens ^{14,15}, Juha Karjalainen^{20,21,22}, Steffen Uebe²³, Ronald B. Melles²⁴, K. Saldas Nair²⁵, Robert Luben ⁵, Mark Simcoe ^{3,26,27}, Nishani Amersinghe²⁸, Angela J. Cree ²⁹, Rene Hohn^{30,31}, Alicia Poplawski ³², Li Jia Chen³³, Shi-Song Rong ^{9,33}, Tin Aung^{34,35,36}, Eranga Nishanthie Vithana ^{34,37}, NEIGHBORHOOD consortium*, ANZRAG consortium*, Biobank Japan project*, FinnGen study*, UK Biobank Eye and Vision Consortium*, GIGA study group*, 23 and Me Research Team*, Gen Tamiya^{38,39}, Yukihiko Shiga⁴⁰, Masayuki Yamamoto ³⁸, Toru Nakazawa^{40,41,42,43}, Hannah Curren ⁴⁴, Ewan Birney ⁴⁴, Xin Wang ⁴⁵, Adam Auton⁴⁵, Michelle K. Lupton¹, Nicholas G. Martin ¹, Adeyinka Ashaye⁴⁶, Olusola Olawoye ⁴⁶, Susan E. Williams ⁴⁷, Stephen Akafo⁴⁸, Michele Ramsay ⁴⁹, Kazuki Hashimoto⁴⁰, Yoichiro Kamatani ^{50,51}, Masato Akiyama^{50,52}, Yukihiko Momozawa⁵³, Paul J. Foster ^{54,55}, Peng T. Khaw ^{54,55}, James E. Morgan⁵⁶, Nicholas G. Strouthidis^{54,55}, Peter Kraft ⁵⁷, Jae H. Kang ⁵⁸, Chi Pui Pang⁵⁹, Francesca Pasutto ²³, Paul Mitchell⁶⁰, Andrew J. Lotery ^{28,29}, Aarno Palotie^{61,62,63}, Cornelia van Duijn^{15,64}, Jonathan L. Haines ^{10,13}, Chris Hammond ³, Louis R. Pasquale ⁶⁵, Caroline C. W. Klaver ^{14,15,66,67}, Michael Hauser^{68,69,70,71}, Chiea Chuen Khor ⁷², David A. Mackey^{7,8,73}, Michiaki Kubo^{74,191}, Ching-Yu Cheng ^{34,35,36,191}, Jamie E. Craig^{75,191}, Stuart MacGregor ^{1,191} & Janey L. Wiggs ^{9,191}

Primary open-angle glaucoma (POAG), is a heritable common cause of blindness world-wide. To identify risk loci, we conduct a large multi-ethnic meta-analysis of genome-wide association studies on a total of 34,179 cases and 349,321 controls, identifying 44 previously unreported risk loci and confirming 83 loci that were previously known. The majority of loci have broadly consistent effects across European, Asian and African ancestries. Cross-ancestry data improve fine-mapping of causal variants for several loci. Integration of multiple lines of genetic evidence support the functional relevance of the identified POAG risk loci and highlight potential contributions of several genes to POAG pathogenesis, including *SVEP1*, *RERE*, *VCAM1*, *ZNF638*, *CLIC5*, *SLC2A12*, *YAP1*, *MXRA5*, and *SMAD6*. Several drug compounds targeting POAG risk genes may be potential glaucoma therapeutic candidates.

A list of author affiliations appears at the end of the paper.

Primarily open-angle glaucoma (POAG) is the leading cause of irreversible blindness globally^{1,2}. The disease is characterized by progressive optic nerve degeneration that is usually accompanied by elevated intraocular pressure (IOP). Neuroprotective therapies are not available and current treatments are limited to lowering IOP, which can slow disease progression at early disease stages; however, over 50% of glaucoma is not diagnosed until irreversible optic nerve damage has occurred^{2,3}.

POAG is highly heritable^{4,5}, and previous genome-wide association studies (GWAS) have identified important loci associated with POAG risk^{6–15}. Despite this success, the POAG genetic landscape remains incomplete and identification of additional risk loci is required to further define contributing disease mechanisms that could be targets of preventative therapies.

The majority of known risk loci for POAG have been identified through GWAS in participants of European descent, followed by replication in other ethnic populations. However, previous observational studies have shown that individuals of African ancestry, followed by Latinos and Asians, have higher POAG disease burden compared to those with European ancestry^{3,16–18}, suggesting important differences in genetic risk and highlighting the need to compare the genetic architecture of these ethnic groups.

In this study, we report the results of a POAG multi-ethnic meta-analysis on 34,179 cases and 349,321 controls, identifying 127 risk loci (44 not previously reported at genome-wide significance levels for POAG). The identified risk loci have broadly consistent effects across European, Asian, and African ancestries. We show that combining GWAS data across ancestries improves fine-mapping of the most likely causal variants for some loci. By integrating multiple lines of genetic evidence we identify the most likely causal genes, some of which might contribute to glaucoma pathogenesis through biological mechanisms related to extracellular matrix cell adhesion, intracellular chloride channels, adipose metabolism, and YAP/HIPPO signaling.

Results

Discovery of previously unreported POAG risk loci in Europeans. We performed a four-stage meta-analysis (Fig. 1). In the

first stage, we conducted a fixed-effect meta-analysis of 16,677 POAG cases and 199,580 controls of European descent. The participating studies are detailed in Supplementary Data 1. We identified 66 independent genome-wide significant ($P < 5e-08$) single nucleotide polymorphisms (SNPs) (Supplementary Data 2), of which 16 were not previously identified (i.e., uncorrelated with previously reported SNPs). There was no evidence of inflation due to population structure (linkage disequilibrium (LD) score regression¹⁹ intercept 1.03, $se = 0.01$, Supplementary Fig. 1A).

Significant POAG risk loci in Asians and Africans. In the second stage, we completed a fixed-effect meta-analysis of 6935 POAG cases and 39,588 controls of Asian descent, and a separate fixed-effect meta-analysis of 3281 POAG cases and 2791 controls of African ancestry (Supplementary Data 1). Ten loci were significantly associated with POAG ($P < 5e-8$) in the meta-analysis of Asian studies (Supplementary Data 3), all of which are known POAG loci, and at least nominally ($P < 0.05$) associated with the European meta-analysis. While only one of these loci had a $P < 0.05$ in Africans, eight had consistent direction of effects. For the African meta-analysis, one locus (rs16944405 within *IQGAPI1*) reached the genome-wide significance level ($P = 3e-08$). This locus has not been previously reported for POAG, and in this study, was not associated with POAG in Europeans ($P = 0.315$) and Asians ($P = 0.075$) (Supplementary Data 3). The LD score regression intercept was 0.99 ($se = 0.009$) for Asians and 0.95 ($se = 0.006$) for Africans, suggesting that these results are not influenced by population structure.

Consistent genetic effect across ancestries. As part of the second stage, we replicated the stage 1 European Caucasian findings in an independent dataset comprising 7,286 self-reported cases and 107,362 controls of European descent from the UK Biobank study (UKBB) (Supplementary Data 1)²⁰, as well as in the meta-analyzed Asian and African datasets described above. We replicated the European Caucasian results in each ancestry group separately (Supplementary Data 2 and Supplementary Fig. 2), followed by combining the three replication datasets in a fixed-




Fig. 1 Study design. This figure summarizes the four stages of this study, as well as the data resources and main analyses/results for each stage.




Fig. 2 Correlation of SNP effect estimates between the European POAG meta-analysis and the replication dataset. The x-axis shows effect estimates in log(OR) scale for the independent genome-wide significant loci obtained from the meta-analysis of POAG in Europeans (16,677 POAG cases vs. 199,580 controls). The y-axis shows the effect estimates in log(OR) scale for the same SNPs obtained from meta-analysis of the following three GWAS data: glaucoma self-reports in UKBB, POAG in Asians, and POAG in Africans (the overall sample size of 17,502 cases and 149,741 controls). Red dots are the previously identified risk loci and blue dots are the previously unreported risk loci identified in this study. Horizontal gray bars on each dot represent the 95% confidence intervals (CIs; mean values $\pm 1.96 \cdot \text{SEM}$) for the effect estimates in Europeans (from the GWAS meta-analysis of 16,677 POAG cases vs. 199,580 controls), and vertical gray bars shows the 95% CIs in the replication dataset (from the GWAS meta-analysis of 17,502 POAG cases vs. 149,741 controls). The blue line is the linear regression line best fitting the data. The shaded area shows the 95% CIs on the regression line. UKBB UK Biobank, POAG primary open-angle glaucoma, OR odds ratio.

effect meta-analysis (17,502 cases and 149,741 controls) to maximize statistical power. Of the 66 significant loci in the European Caucasian meta-analysis, 56 were nominally significant ($P < 0.05$), and 37 after Bonferroni correction ($P < 7.6e-04$) in the meta-analyzed replication cohort. The effect sizes had a Pearson correlation coefficient (r) = 0.82 (Fig. 2).

There was moderately high cross-ancestry concordance both for genome-wide significant loci and across the genome. For the genome-wide significant SNPs, the European SNP effects were correlated (Pearson correlation coefficient (r) = 0.68 [95% confidence intervals (CIs) 0.38–0.97] and r = 0.44 [95% CIs 0.20–0.69]) with Asian and African ancestries, respectively (Supplementary Fig. 2B, C). Of the 68 SNPs available in the Asian meta-analysis, 60 (88%) showed the same direction of effect as European Caucasians, and of the 66 SNPs available in the African meta-analysis, 55 (83%) showed the same direction as European Caucasians. The genetic correlation across the genome estimated using the approach implemented in Popcorn v0.9.9²¹ was even higher: r = 0.85 (95% CIs 0.70–1.00) for European-Asian and r = 0.75 (95% CIs -0.93 to 2.43) for European-African. Although the concordance amongst the top SNPs was clear for the European-African comparison, larger sample sizes will be required to narrow the CIs on the European-African genome-wide correlation estimate.

Discovery of previously unknown POAG risk loci in the cross-ancestry meta-analysis. In the third stage, given the large genetic correlation between ancestries, we performed a fixed-effect meta-analysis of the results from stage 1 and 2 (34,179 cases vs. 349,321 controls) and identified 127 independent genome-wide significant loci, located at least >1 Mb apart (Fig. 3 and Supplementary Fig. 3). Of these, 44 loci were not previously associated with POAG at genome-wide significance levels (Supplementary Data 4). All loci identified in the European meta-analysis were also significant at the genome-wide level in the combined ancestry meta-analysis except for three loci, two of which were not previously identified (*OVOL2* and *MICAL3*), and one previously reported (*EGLN3/SPTSSA*). Of note, four of the risk loci (*MXRA5-PRKX*, *GPM6B*, *NDP-EFH2*, and *TDGF1P3-CHRD1*) are on the X chromosome, representing the first POAG risk loci on a sex chromosome. We also identified an association of a human leukocyte antigen (HLA) gene (*HLA-G/HLA-H*) with POAG. All the lead SNPs have MAF > 0.01 in Europeans, except for two variants: rs74315329 (MAF = 0.0026 in 1000G Europeans) a well-known nonsense variant in *MYOC*^{22,23}, and rs190157577 (MAF = 0.0013 in 1000G Europeans) an intronic variant in *LINC02141/LOC105371299*.

The POAG risk loci were strongly replicated in 23andMe. In the fourth stage, we validated the association of the genome-wide significant SNPs from stage 3 in a dataset comprising 43,254 participants with self-reported POAG (defined as those who reported having glaucoma excluding angle-closure glaucoma or other types of glaucoma) and 1,471,118 controls from 23andMe, Inc. Of the 127 loci, the association results for 125 SNPs were available in 23andMe, 120 of which (96%) were replicated at $P < 0.05$, and 106 (85%) after Bonferroni correction for 125 independent tests (Supplementary Data 4). The correlation of the effect size was r = 0.98 (95% CIs 0.977–0.989). In total, the genome-wide significant loci in this study (N = 127) collectively explain 9.4% of the POAG familial risk. The previously known loci (N = 83) explain 7.5% of the familial risk, and the previously unreported loci (N = 44) explain an additional 1.9%.

Most of the risk loci associated with POAG involve known glaucoma-related endophenotypes. Several highly heritable endophenotypes are related to POAG risk including IOP, structural variation of the optic nerve characterized as vertical cup-to-disc ratio (VCDR) and variation in thickness of the retina cell layers including the retinal nerve fiber layer (RNFL) and the ganglion cell inner plexiform layer (GCIPL)²⁴.

All POAG risk variants identified to date have also been associated with either IOP or with VCDR or both. We investigated the association of the POAG loci identified in this study with IOP and VCDR, using previous GWAS data for IOP (N = 133,492)¹¹ and for VCDR (N = 90,939)¹⁵. Figure 4a shows that the majority of loci (89 of 123; four were unavailable for IOP) are also associated with IOP (red and green dots on Fig. 4a). For the 34 loci with unclear effect on IOP (purple and blue dots on Fig. 4a, full data in Supplementary Data 5), we plotted the POAG effect sizes against VCDR effect sizes and determined that 24 of the 32 SNPs (2 SNPs unavailable for VCDR), have a clear effect on VCDR (purple dots on Fig. 4b). Eight of the POAG loci did not appear to have a clear effect on IOP or VCDR, although a small effect on glaucoma via a small change in IOP or VCDR could not be ruled out. The overall correlation of effect sizes between all POAG risk loci and IOP was 0.53, and between POAG and VCDR was 0.31, in line with previously published genetic correlation estimates²⁵. To better visualize clustering of the POAG SNPs based on their effect on IOP/VCDR, we created




Fig. 3 Manhattan plots for the cross-ancestry meta-analysis. Each dot represents a SNP, the x-axis shows the chromosomes where each SNP is located, and the y-axis shows $-\log_{10}$ P-value of the association of each SNP with POAG in the cross-ancestry meta-analysis (34,179 cases vs. 349,321 controls). The red horizontal line shows the genome-wide significant threshold (P -value = $5e-8$; $-\log_{10}$ P-value = 7.30). The nearest gene to the most significant SNP in each locus has been labeled.

a heatmap by clustering SNPs based on Pearson correlation between effect estimates of SNPs on POAG, IOP, and VCDR (Supplementary Fig. 4).

Of the 127 POAG genome-wide significant lead SNPs, 116 were available in a GWAS of GCIPL thickness ($N = 31,536$; Supplementary Data 6). Of these, 14 loci were associated with GCIPL thickness at nominal significance threshold ($P < 0.05$) and four (*PLEKHA7*, *MAPT*, *LINC01214-TSC22D2*, and *POU6F2*) after Bonferroni correction for the number of tests ($P < 0.05/116$). Similarly, 13 loci were nominally associated with RNFL, and three (*PLEKHA7*, *MAPT*, and *SIX6*) after Bonferroni correction. These results suggest that these loci may impact glaucoma pathogenesis through modulation of retinal thickness.

Given that three POAG risk loci that we identified (loci containing *MAPT*, *CADM2*, and *APP*) have also been implicated in Alzheimer's disease (AD) and dementia^{26–28}, we asked whether the same causal variants may underlie these loci and whether there is evidence for genetic sharing in any of the other genome-wide significant POAG loci. Applying the Bayesian-based colocalization method, eCAVIAR²⁹, to the cross-ancestry and European POAG GWAS meta-analyses and the publicly available AD GWAS data³⁰ for 21,982 cases and 41,944 controls³⁰ of European descent, we found no evidence for sharing of causal variants in the 123 (cross-ancestry) or 66 (European) autosomal POAG loci (Colocalization Posterior Probability (CLPP) < 0.01 ; Supplementary Data 7). With a larger AD GWAS meta-analysis of 71,880 cases and 383,378 controls^{30,31}, there was weak support for colocalization at six loci (CLPP = 0.01–0.14; four loci from the cross-ancestry and three from the European POAG meta-analysis

with one overlapping locus; see Supplementary Data 8), though none of these POAG loci reached genome-wide significance in the AD GWAS (AD variant P -values on the order of 10^{-4} to 0.05). We note that the colocalization results with this larger AD GWAS meta-analysis^{30,31} might be slightly inflated due to the large overlap of UK biobank samples between the POAG and AD meta-analyses. We further estimated the genome-wide genetic correlation between POAG and AD using LD score regression (LDSR)³² that adjusts for sample overlap, on the two AD GWASs;^{30,31} the correlation estimates were 0.03 (95% CIs: -0.11 – 0.16 ; $P = 0.7$) and 0.14 (95% CIs: 0.003–0.28; $P = 0.049$), respectively.

We next investigated genetic correlation between POAG and a range of other traits using bivariate LDSR³² through the LD Hub platform (<http://ldsc.broadinstitute.org/ldhub/>). Only glaucoma, self-report glaucoma, and “Other eye problems” were significantly associated after adjustment for multiple testing for 758 traits ($P < 6.6e-05$; Supplementary Data 9). Some other traits in UKBB such as myopia (short-sightedness); systolic blood pressure; seeing a psychiatrist for nerves, anxiety, tension or depression; and suffering from nerves, showed some evidence for association at $P < 0.003$ (Supplementary Data 9).

Cross-ancestry fine-mapping. Incorporating GWAS data across European, Asian, and African ancestries allowed us to improve fine-mapping of the most likely causal variants. For 10 loci (including previously unidentified loci *GJA1/HSF2*, *SEPT7*, and *MXRA5/PRKX*), the posterior probability of finding a causal SNP




Fig. 4 Association of the POAG risk loci with IOP and VCDR. The x-axes show POAG effect estimates in log(OR) scale for the independent genome-wide significant loci obtained from the cross-ancestry meta-analysis. The y-axes show the effect estimates for the same SNPs obtained from the meta-analysis of IOP in UKBB + IGGC (mmHg scale; **a**) and the meta-analysis of VCDR in UKBB + IGGC (**b**). Blue line shows the regression line for IOP (**a**) and VCDR loci (**b**). Orange dots represent SNPs having $P < 0.05$ for IOP, purple dots $P < 0.05$ for VCDR, green dots $P < 0.05$ for both IOP and VCDR, and blue dots $P > 0.05$ for both IOP and VCDR. Horizontal gray bars on each dot represent the 95% confidence intervals (CIs; mean values $\pm 1.96 \cdot \text{SEM}$) for the POAG effect estimates (34,179 cases vs. 349,321 controls), and vertical gray bars shows the 95% CIs for IOP ($N = 133,492$; **a**) and VCDR ($N = 90,939$; **b**). The shaded area shows the 95% CIs on the regression line. Although none of the blue dots show an expected trend of association with IOP in **a** (their 95% CIs do not overlap with the regression line), the majority of them show a trend of association for VCDR in **b**. UKBB UK Biobank, IGGC International Glaucoma Genetics Consortium, IOP intraocular pressure, VCDR, vertical cup-to-disc ratio, POAG primary open-angle glaucoma, OR odds ratio.

in Europeans improved after including Asian and African data (improvements from posterior probabilities < 0.9 to > 0.9 or from < 0.8 to > 0.8 ; Supplementary Data 10). For eight loci (of which *THRB* and *SMAD6* were not known), although the posterior probability of a SNP being causal in Europeans was high (> 0.9 at least for one SNP), there was still a slight improvement after including the other ancestries (Supplementary Data 10). In contrast, the cross-ancestry data made fine-mapping worse for three loci where the posterior probabilities in Europeans were > 0.8 but declined to < 0.8 after incorporating data from the other ancestries. For the rest of the loci, the posterior probabilities did not change significantly after including Asian and African data. Overall, the best causal SNPs in Europeans changed for 52 of 127 loci after including data from the other ancestries (Supplementary Data 10). For the remaining 75 loci, at least one SNP remained the best causal SNP in both fine-mapping using European data alone, as well as across ancestries, and 23 of the 127 lead SNPs identified in the meta-analysis remained the best causal SNP in cross-ancestry fine-mapping.

Gene-based and pathway-based results. We performed gene-based and pathway-based tests using MAGMA v1.07b³³ for each ancestry separately, followed by combining P -values across ancestries using Fisher’s combined probability test³⁴. We identified 205 genes that passed the gene-based Bonferroni-corrected threshold ($P < 0.05/20174$), corresponding to an additional seven independent risk loci located at least > 1 Mb apart from the risk loci identified in the single-variant-based test. Supplementary Data 11 presents significant genes within these seven loci. Expression of the risk genes identified in MAGMA gene-based analysis were significantly enriched in artery and nerve tissues,

reflecting the widely recognized neuronal and vascular character of glaucoma (Supplementary Fig. 5A, B).

Pathway analysis identified 21 significant gene-sets surviving the Bonferroni-corrected threshold ($P < 0.05/10678$). These included previously identified pathways such as collagen formation and vascular development^{10,11}, and highlighted additional pathways involved in lipid binding and transportation such as apolipoprotein binding and negative regulation of lipid storage (Supplementary Data 12). Genes involved in these pathways that demonstrated suggestive association ($P < 5e-05$) with POAG in the MAGMA gene-based test are summarized in Supplementary Data 13.

Functional relevance of the identified POAG risk loci. We used multiple lines of genetic evidence to investigate the functional relevance of the identified risk loci, and to prioritize causal variants and target genes. A summary of these results for the previously unknown loci is provided in Table 1, with additional details presented in Supplementary Data 14. The following paragraphs describe these findings in further detail.

First, the relevance of the identified risk loci was investigated by examining their roles in regulation of gene expression, as well as chromatin interactions. Approximately 76% (96 out of 127) of the lead SNPs or those in high LD ($r^2 > 0.8$) with the lead SNPs have also been reported to be significant expression quantitative trait loci (eQTLs) (FDR < 0.05) in various tissues (Supplementary Data 14 and 15). Moreover, the identified risk loci have 34,724 unique significant (FDR $< 1e-6$) chromatin interactions in various tissues/cell lines involving 4882 genes (Supplementary Fig. 6). Of these, 425 genes overlap with the eQTL genes (286 genes if only considering eQTL results for the genome-wide significant SNPs).

Table 1 Summary of the previously unreported POAG risk loci annotation and functional studies.

Lead SNP	Annotation	Nearest gene	Causal ^a	Chromatin interaction ^b	eQTL any tissue ^c	eQTL retina ^d	Protein altering ^e	CADD > 12.37 ^f	Gene-based tests ^g	Genes within significant pathways ^h
rs172531	Intron	RERE	NO	RPL7P11	RERE	RERE	NO	NO	RERE	NO
rs941125	Intron	GLIS1	NO	SLC25A3P1	GLIS1	NO	NO	NO	GLIS1	NO
rs4076000	Intergenic	ELOCP18/RPE65	NO	CTBP2P8	WLS	NO	NO	NO	NO	NO
rs12566440	Intron	GPR88	NO	VCAM1	VCAM1	VCAM1	NO	NO	GPR88	NO
rs4542196	Intron	DDR2	NO	DDR2	DDR2	NO	NO	NO	NO	DDR2
rs12623251	Intergenic	TRIB2	YES	ACO13471.1	TRIB2	NO	NO	NO	TRIB2	NO
rs6713914	Intron	LOC105374754	NO	ACO09970.1	NO	NO	NO	YES	NO	NO
rs12613800	Intron	ZNF638	NO	RNU6-105P	ZNF638	ZNF638	ZNF638	NO	ZNF638	NO
rs9852634	Intron	THRB	YES	RPL31P20	NO	NO	NO	NO	NO	NO
rs1500708	Intron	ARHGEF3	YES	ARHGEF3-AS1	NO	NO	NO	NO	ARHGEF3-AS1	NO
rs6437582	Intergenic	ALCAM	YES	AC074043.1	ALCAM	ALCAM	NO	NO	NO	NO
rs10517281	Intron	SCFD2	YES	Multiple ⁱ	FIPL1	NO	NO	YES	SCFD2	NO
rs57400569	Intron	FAM13A	YES	Multiple	FAM13A	NO	NO	YES	NO	NO
rs17527016	Intergenic	PITX2	NO	AC083795.1	NO	NO	NO	YES	NO	PITX2
rs6552711	Intron	STOX2	NO	ENPP6	NO	NO	NO	NO	NO	NO
rs407238	Intergenic	HLA-G	NO	Multiple	NO	NO	NO	NO	Multiple	NO
rs3777588	Intron	CLIC5	NO	MIR4642	CLIC5	CLIC5	NO	YES	CLIC5	NO
rs7760346	Intergenic	GJA1/HSF2	NO	Multiple	HSF2	Multiple	NO	NO	NO	GJA1
rs2811688	Intron	SLC2A12	NO	TBPL1	SLC2A12	SLC2A12	NO	NO	SLC2A12	NO
rs2191828	Intron	CREB5	NO	ACO05105.1	NO	NO	NO	NO	NO	NO
rs6957752	Intergenic	SEPT7	NO	Multiple	RP11-379H18.1	RP11-379H18.1	NO	NO	NO	NO
rs7805468	Intergenic	PCLO/SEMA3E	NO	AC079799.1	NO	NO	NO	NO	SEMA3E	SEMA3E
rs2515437	Intron	ANGPT2/MCPH1	NO	Multiple	NO	NO	ANGPT2	NO	NO	ANGPT2
rs35740987	Intron	GTF2E2	NO	Multiple	GTF2E2	NO	NO	NO	GTF2E2	NO
rs61751937	Missense	SVEP1	NO	AL162414.1	NO	NO	SVEP1	YES	NO	NO
rs6602453	Intron	CELF2	NO	AL136369.1	SFTA1P	NO	NO	NO	NO	ECHDC3
rs72837408	Downstream	MIR4483/PLEKHS1	NO	ADRB1	RP11-211N11.5	NO	NO	NO	Multiple	NO
rs7120067	Intron	YAP1	NO	AP000942.2	YAP1	NO	NO	NO	YAP1	YAP1
rs10444329	Downstream	CADM1	NO	AP000462.3	CADM1	NO	NO	NO	NO	NO
rs7972874	Intergenic	PTHLH/CCDC91	NO	PTHLH	CCDC91	CCDC91	NO	NO	NO	NO
rs4903352	Intron	TLL5	NO	TGFB3-AS1	FLVCR2	NO	NO	NO	Multiple	TGFB3
rs72692789	Intron	SYNE3/SNHG10	NO	Multiple	NO	NO	NO	NO	NO	NO
rs2439386	Intron	SMAD6	NO	NO	SMAD6	NO	NO	NO	SMAD6	SMAD6
rs8038628	Intergenic	SLCO3A1/SV2B	NO	SLCO3A1	NO	NO	NO	NO	NO	NO
rs190157577	Intron	LINC02141/LOC105371299	NO	NO	NO	NO	NO	YES	NO	NO
rs242559	Intron	MAPT	NO	Multiple	Multiple	Multiple	Multiple	NO	Multiple	MAPT
rs1348518145	Intron	NPEPPS	NO	KPNB1	NO	NO	NPEPPS/TBKBP1	NO	NPEPPS	NO
rs6124885	Intron	EYA2	NO	MIR3616	NO	NO	NO	NO	NO	NO
rs13049669	Intergenic	GABPA/APP	NO	APP	MRPL39	NO	NO	NO	NO	APP
rs13050568	Intron	PSMG1/LOC107985484	YES	RPSAP64	AF064858.11	NO	NO	NO	NO	NO
rs12846405	Intergenic	MXRA5/PRKX	NO	MXRA5	MXRA5	NO	NO	NO	MXRA5	Multiple
rs66819623	Intron	GPM6B	NO	ACO03035.1	GEMIN8	NO	NO	NO	NO	NO
rs17146835	Intergenic	NDP/EHFC2	NO	AL034370.1	NO	NO	NO	NO	NO	Multiple
rs12013156	Intergenic	TDGF1P3/CHRD1	NO	NO	NO	NO	NO	NO	NO	CHRD1

^aThis column indicates whether the GWAS lead SNP was identified to be the most probable causal SNP across ancestries in the multi-ethnic fine-mapping analyses performed using the software PAINTOR.

^bWhere the GWAS lead SNP or SNPs in LD $r^2 > 0.8$ with the lead SNP overlap with one end of a chromatin interaction, the most significant gene involved in this interaction has been shown.

^cWhere the GWAS lead SNP or SNPs in LD $r^2 > 0.8$ with the lead SNP is an eQTL in any GTEx tissue or the other eQTL databases used in this study (see the Methods), the most significant target gene has been shown.

^dWhere the GWAS lead SNP or SNPs in LD $r^2 > 0.8$ with the lead SNP is an eQTL in retina in EyeGEx study, the most significant target gene has been shown.

^eWhere the GWAS lead SNP is a protein-altering variant or in LD $r^2 > 0.8$ with a protein-altering variant, the corresponding gene has been shown.

^fThis column indicates whether the GWAS lead SNP has a CADD score > 12.37.

^gThis column shows the loci in which one or multiple genes were significant in any of the gene-based tests (MAGMA, MetaXcan, SMR, and FOCUS) used in this study. "Multiple" indicates that several genes are involved. These genes have been named in Supplementary Data 14.

^hThis column shows the loci for which the reported nearest genes or the significant genes identified in the gene-based tests above are members of at least one significant POAG pathway identified in this study.

ⁱ"Multiple" indicates several genes.

In addition, the lead SNPs or SNPs with LD $r^2 > 0.8$ with the lead SNPs for 124 risk loci identified in this study overlap with one end of these chromatin interactions (Supplementary Data 14).

Additional support for the pathogenicity of the POAG risk loci comes from the predicted pathogenicity scores: 20 SNPs had CADD scores > 12.37, suggesting that these SNPs have deleterious effects (Supplementary Data 16)³⁵. Overall, three lead SNPs are protein-altering variants and 12 lead SNPs are in high LD ($r^2 > 0.8$) with a protein-altering variant (Supplementary Data 14), suggesting pathogenic effects through protein-coding roles of these variants (e.g., rs61751937 a missense variant in *SVEP1*). In addition, 24 SNPs had RegulomeDB³⁶ scores ≤ 3 , supporting regulatory roles for these SNPs (Supplementary Data 16).

To investigate which risk loci are more likely to affect POAG by modulating gene expression, we used two transcriptome-wide association study (TWAS) approaches: Summary Mendelian randomization (SMR)³⁷ and MetaXcan³⁸. For MetaXcan, we used our POAG cross-ancestry meta-analysis statistics, RNA-seq and genotype data from peripheral retina (EyeGEx)³⁹ and 44 GTEx tissues. Following Bonferroni correction for the maximum number of genes tested ($N = 7209$) in 45 tissues ($P < 1.5e-07$), we identified 100 significant genes, which were selected as the most likely causal genes based on the integration of eQTL data (also see below and Supplementary Data 14 and 17). Of these significant genes, three (*AKR1A1*, *DDIT4L/LAMTOR3*, and *C4orf29*) were located > 1 Mb apart from (the other loci) identified using single-

variant and other gene-based tests performed in this study and were not previously reported for POAG (Supplementary Data 17). In a post hoc analysis looking solely at retina, two additional genes (*CNTF* and *MPHOSPH9*) were significant (given Bonferroni correction threshold for 6508 genes in retinal tissue).

Additionally, we integrated our GWAS meta-analysis summary statistics with eQTL data from blood (CAGE eQTL summary data, $N = 2765$) and retina (EyeGEx eQTL data, $N = 406$) using SMR. Given that these eQTL data were obtained from people of European descent, we restricted this analysis to our European meta-analysis to ensure that different gene expression and LD structure patterns between ancestries did not influence the SMR findings. In retina and blood, 16 genes passed the SMR significance threshold corrected for the maximum number of 8516 genes tested in two tissues ($P < 2.9e-06$), of which eight had a $P > 0.05$ in the heterogeneity in dependent instruments (HEIDI) test³⁷ implemented in SMR, suggesting that the same association signals drive both gene expression and POAG risk, at these loci (Supplementary Data 18). Although the majority of the risk loci identified through the MetaXcan and SMR approaches were also identified in the meta-analysis, these analyses help with prioritizing the most likely functionally relevant genes. To further identify the most plausible causal genes based on gene expression data, we used the approach implemented in FOCUS v0.5⁴⁰, a probabilistic framework that assigns a posterior probability for each gene causally driving TWAS associations in multiple tissues (Supplementary Data 19 summarizes the genes with a posterior probability > 0.6).

Integrating data from several lines of evidence described above, as well as the cross-ancestry fine-mapping and genetic pathways, provided support for specific genes potentially influencing POAG risk particularly *RERE*, *VCAM1*, *ZNF638*, *CLIC5*, *SLC2A12*, *YAPI*, *MXRA5*, and *SMAD6* (Table 1 and Supplementary Data 14). For example, rs3777588, a lead GWAS SNP in this study, is an intronic variant within *CLIC5*. The CADD score for this variant is 16.58, providing support for the pathogenicity of this variant (determined by a CADD score > 12.37). The lead SNP is also an eQTL for *CLIC5* in both GTEx and retina, and gene-based analysis by incorporating eQTL data supported the involvement of *CLIC5* in POAG risk. This approach also helped to select best genes near the lead SNPs or to shift the focus from the nearest genes to genes further away. For example, rs12846405, a lead GWAS SNP in this study, is an intergenic variant located between *MXRA5* and *PRKX*. Based on integration of eQTL data and gene-based analysis, *MXRA5* was prioritized as the most likely causal gene in this locus.

Differential expression of the previously unknown risk loci in eye tissues. We investigated the expression of the genes nearest to the lead SNP for the novel loci in 21 healthy eye tissues¹¹ (Supplementary Data 20 and Supplementary Fig. 7). Clustering analysis shows that the majority of these genes were expressed in eye tissues (Supplementary Fig. 7A). We examined the differential expression of the previously unreported genes in ocular tissues likely to be involved in POAG pathogenesis, namely trabecular meshwork, ciliary body and optic nerve head, and found 36/51 (71%) of the genes differentially expressed in these tissues compared to the other eye tissues tested in this study (Supplementary Data 20 and Supplementary Fig. 7B).

Drug targets. At least 16 of the POAG risk genes (nearest to the lead SNPs) are targeted by existing drugs, some of which are already in use/clinical trials for several eye or systemic diseases (Supplementary Data 21). The functional relevance of 14 of these 16 drug target genes is supported by the bioinformatic functional

analyses we used in this study (i.e., eQTL, chromatin interaction, etc; Supplementary Data 21). We discuss the relevance of some of these drugs in the discussion section below.

Sex-stratified meta-analysis. We identified a very high genetic correlation ($rg = 0.99$, $se = 0.06$) between POAG in men versus women (European stage 1 and UKBB self-reports combined). We also performed cross-ancestry, sex-stratified meta-analyses using a subset of the overall study with sex-stratified GWAS available (Supplementary Data 1; Supplementary Data 22 and 23; Supplementary Fig. 1C, D). Only one signal near *DNAH6* appeared to have a female-specific effect (2:84828363[CA], $OR = 1.6$, $P = 3.28e-09$ for women; $OR = 1.05$, $P = 0.56$ for men).

Subtype-stratified meta-analysis. Based on IOP levels, POAG can be classified into two major subtypes: high-tension glaucoma (HTG) in which IOP is increased (> 21 mmHg), and normal tension glaucoma (NTG) in which IOP remains within the normal range. We performed cross-ancestry subtype-specific meta-analyses using 3247 cases and 47,997 controls for NTG (Normal tension glaucoma defined as glaucoma with $IOP < 21$ mmHg), and 5144 cases and 47,997 controls for HTG (high-tension glaucoma with $IOP > 21$ mmHg (Supplementary Data 24 and 25 and Supplementary Fig. 1E, F). All NTG and HTG loci were also significantly associated with the overall POAG meta-analysis except for one locus near *FLNB* that was significant for NTG (lead SNP rs12494328[A], $OR = 1.18$, $P = 1.7e-08$), but did not reach the significance threshold for POAG overall ($P = 7.5e-07$). However, this SNP was significant in the 23andMe replication study (rs12494328[A], $OR = 1.06$, $P = 1.35e-12$), and has previously been associated with optic nerve head changes⁴¹. Overall, all NTG loci were at least nominally associated ($P < 0.05$) with HTG (and vice versa) except for rs1812974 (top SNP near *ARHGAP12*). Although this SNP had the same direction of effect for NTG, the effect was significantly larger for HTG than NTG ($P = 0.007$). Similarly, several other loci had significantly larger effects on one subtype (e.g., *CDKN2B-AS1*, *FLNB*, and *C14orf39* had larger effects on NTG than HTG) (Supplementary Data 24 and 25). Overall, the genetic correlation between NTG and HTG was estimated to be 0.58 ($se = 0.08$) using LD score regression and the meta-analysis summary data from Europeans.

Discussion

In this large multi-ethnic meta-analysis for POAG, we identified 127 risk loci for POAG, of which 44 were not previously identified. We also identified additional risk loci using gene-based tests and highlighted genetic pathways involved in the pathogenesis of POAG. We observed relatively consistent genetic effects for POAG across ancestries. The risk loci include genes that are highly expressed in relevant eye tissues, nerves, arteries, as well as tissues enriched with these components. Functional relevance of the identified risk loci were further supported by eQTL and chromatin interaction data.

We identified a significant correlation between the POAG effect sizes of genome-wide significant SNPs, as well as all the SNPs throughout the genome, across Europeans, Asians, and Africans. Although previous studies have suggested that the genetic architecture of POAG might differ between Africans and Europeans⁴², we observed a moderate correlation ($r \sim 0.45$) between effect sizes of the POAG risk loci in Europeans and Africans (Supplementary Fig. 2C), and the correlation was higher between Europeans and Asians ($r \sim 0.7$). Although the overall correlation is moderately high across ancestries, there are genomic regions where the LD pattern differs by ancestry and our fine-mapping approach showed that incorporating GWAS data

across ancestries improved the probability of finding a causal variant for 18 loci in this study, including known (e.g., *AFAP1* and *RELN* loci) and unknown (e.g., *GJA1/HSF2* and *SEPT7*) loci. However, the most probable causal variants in Europeans remained the same for ~60% (75 out of 127) of the risk loci even after incorporating Asian and African GWASs. Overall, due to the relatively lower statistical power of our African studies, the fine-mapping results in this study were not strongly influenced by African GWASs, emphasizing that larger African POAG GWASs are required for better cross-ancestry fine-mapping in the future.

We also identified a previously unknown association of a human leukocyte antigen (*HLA-G/HLA-H*) with POAG. The HLA system is a gene complex encoding the major histocompatibility complex proteins in humans. These cell-surface proteins are responsible for the regulation of the human immune system. The most significant SNP in this region (rs407238) has been associated at the genome-wide significance level for other traits such as Celiac disease, intestinal malabsorption, disorders of iron metabolism, multiple blood traits, hyperthyroidism, multiple sclerosis, hip circumference, and weight (https://genetics.opentargets.org/variant/6_29839124_C_G). The mechanism of action of the lead SNP appears to be via IOP (UKBB IOP GWAS $P = 8.8e-06$).

The gene-sets enriched for the risk loci identified in this study indicate two major pathogenic mechanisms for POAG: (1) vascular system defects, mainly the molecular mechanisms contributing to blood vessel morphogenesis, vasculature development, and regulation of endothelial cell proliferation, and; (2) lipid binding and transportation—mainly the molecular mechanisms involved in intracellular lipid transport, apolipoprotein binding, negative regulation of lipid storage, and positive regulation of cholesterol efflux. Involvement of the vascular system in the pathogenesis of POAG is further supported by our results showing enrichment of the expression of the POAG risk genes in arteries and vessels. Molecular targets in these pathways can be potential candidates for treatment of POAG. Two of the significant gene-sets in this study (phagocytosis engulfment and negative regulation of macrophage derived foam cell differentiation) suggest an important role of immune system defects in increasing the risk of POAG.

Integrating several lines of genetic evidence provided support for specific genes within the identified risk loci that could influence risk through known and unknown processes. *MXRA5* and *SMAD6* are both involved in transforming growth factor (TGF) beta-mediated extracellular matrix remodeling^{43,44}, a process known to contribute to POAG risk⁴⁵. Additionally, a *SVEP1* missense allele was associated with POAG risk (rs61751937). *SVEP1* encodes an extracellular matrix protein that is essential for lymphangiogenesis in mice, through interaction with *ANGPT2* (the product of another POAG risk gene identified in this study), and modulation of expression of *TEK* and *FOXC2* in knockout mice⁴⁶. Lymphangiogenesis has an important role in the development of Schlemm's canal required for outflow of fluid from the eye^{47,48}, and two other genes necessary for lymphangiogenesis and Schlemm's canal development (*TEK*, *ANGPT1*) cause childhood glaucoma^{49,50}. Interestingly, *SVEP1* was shown to be a modifier of *TEK*-related primary congenital glaucoma⁵¹. *VCAM1* is an extracellular matrix cell adhesion molecule involved in angiogenesis and possibly regulation of fluid flow from the eye⁵². *RERE* mutations are a cause of neurodevelopmental disorders that can involve the eye⁵³, providing further evidence for a role of ocular development in adult glaucoma⁵⁴. While *RERE* has also been associated with VCDR⁵⁵, this is the first association with POAG.

Genes involved in biological processes not previously known to contribute to glaucoma have also been implicated by this study. *CLIC5* encodes a chloride channel that functions in

mitochondria⁵⁶ and could have a role in ocular fluid dynamics. *ZNF638* is a zinc finger protein that regulates adipose differentiation⁵⁷ and has been implicated in the genetic regulation of height⁵⁸. *SLC2A12* is a glucose transporter that is also involved in fat metabolism⁵⁹. *YAP1* is an oncogene that is a main effector of the HIPPO tumor suppressor pathway and apoptosis inhibitor⁶⁰, processes that could influence retinal ganglion cell survival in glaucoma. In mice, heterozygous deletion of *Yap1* leads to complex ocular abnormalities, including microphthalmia, corneal fibrosis, anterior segment dysgenesis, and cataract⁶¹.

Several proteins encoded by genes within the identified POAG risk loci are targets of some currently approved drugs. For instance, *COL4A1* is targeted by ocriplasmin, a collagen hydrolytic enzyme that is currently used to treat vitreomacular adhesion (adherence of vitreous to retina). This drug can degrade the structural proteins including those located at the vitreoretinal surface⁶². Clinical trials are in progress to evaluate ocriplasmin therapy for several eye conditions including macular degeneration, diabetic macular edema, macular hole, and retinal vein occlusion. Some other drug candidates targeting proteins encoded by POAG-associated loci are also currently under consideration for treating dementia and cardiovascular diseases including acitretin, a retinoid receptor agonist targeting RARB, which has been considered for treatment of AD in ongoing clinical trials. Also, dipyrindamole, a 3',5'-cyclic phosphodiesterase inhibitor, targets *PDE7B* and current clinical trials are testing therapies based on dipyrindamole for diseases such as stroke, coronary heart disease, ischemia reperfusion injury, and internal carotid artery stenosis. Given that our pathway analyses highlighted the involvement of vasculature development and blood vessel morphogenesis in POAG pathogenesis, dipyrindamole could be a potential therapy for POAG through modulation of blood flow, which can be defective in POAG^{63,64}. Further studies to confirm the functionality of these POAG risk genes in vivo and in vitro may support the suitability of repurposing these drugs as alternative treatments for POAG. Moreover, comprehensive fine-mapping is required to identify the most likely causal genes that can be targeted by currently approved drugs.

This study has several strengths and limitations. The main strength includes identification of risk loci contributing to the development of POAG across ethnic groups, an advance over prior POAG GWAS that have mainly focused on individuals from a single ancestry group. We showed that combining GWAS data across ancestries increases the power of gene mapping for POAG. Another strength is the integration of GWAS, gene expression, and chromatin interaction data to investigate the functional relevance of the identified loci, as well as to identify the most plausible risk genes.

A limitation of this study is that although the majority of the cases were clinically confirmed POAG, our data included >7200 glaucoma cases from the UKBB obtained through self-reports. However, we observed a very high concordance between the GWAS results for clinically validated cases versus self-report. Additionally, the vast majority of our results replicated in self-report data from 23andMe. The second limitation of this study is its relatively low statistical power for the subtype-specific analyses (especially for the NTG subset), limiting the ability of this study to identify subtype-specific loci. Larger NTG GWASs are required to dissect the genetic heterogeneity between POAG subtypes. Third, although where possible each participating study adjusted for the effect of age in their association testing prior to the meta-analysis, in a subset of studies, cases and controls were not matched for age and future studies should fully investigate the effect of the identified risk loci across different age strata, particularly for loci where certain alleles are strongly associated with other age-related conditions. Finally, although we investigated the

functional relevance of the identified risk loci using bioinformatic analyses, we did not confirm their functionality *in vitro* and *in vivo*. Further studies to investigate the biological roles of these risk loci with respect to POAG pathogenesis in relevant eye tissues will further shed light on the molecular etiology of POAG.

In conclusion, this study identified a strong cross-ancestry genetic correlation for POAG between Europeans, Asians, and Africans, and identified 127 genome-wide significant loci by combining GWAS results across these ancestries. The cross-ancestry data improved fine-mapping of causal variants. By integrating multiple lines of genetic evidence, we implicate previously unknown biological processes that might contribute to glaucoma pathogenesis including intracellular chloride channels, adipose metabolism and YAP/HIPPO signaling.

Methods

Study design and participants. We obtained 34,179 POAG cases and 349,321 controls including participants of European, Asian, and African descent from 21 independent studies across the world. Number of cases and controls, and distribution of age and sex for each study are summarized in Supplementary Data 1. The phenotype definition and additional details such as genotyping platforms for each study are provided in Supplementary Information. For most of the studies, we restricted glaucoma to POAG based on the ICD9/ICD10 criteria. However, considering that POAG constitutes the majority of glaucoma cases in Europeans⁶⁵, we also included 7286 glaucoma self-reports from UK Biobank to replicate findings from the ICD9/ICD10 POAG meta-analysis in Europeans and to maximize the statistical power of the final stage meta-analysis (please see below). Informed consent was obtained from all the participants, and ethics approval was obtained from the ethics committee of all the participating institutions.

We performed a four-stage meta-analysis to combine GWAS data from the participating studies. In the first stage, we conducted a meta-analysis of the POAG GWAS in Europeans (16,677 POAG cases and 199,580 controls). In the second stage, we performed independent meta-analyses of POAG GWAS in Asians (6935 cases and 39,588 controls) and in Africans (3281 cases and 2791 controls) (Supplementary Data 1). As part of the second stage, the Asian and African meta-data, as well as data from a GWAS of 7286 self-report glaucoma cases and 107,362 controls of European descent from UKBB were used to validate the findings from the European Caucasian meta-analysis. The UKBB self-report GWAS was completely independent of the UKBB IC9/ICD10 POAG GWAS; all the UKBB POAG cases and controls from the first stage, as well as their relatives ($\hat{P} > 0.2$), were removed from the self-report GWAS dataset. In the third stage, we combined the results from stage 1 and 2 to increase our statistical power to identify POAG risk loci across ancestries. In the fourth stage we replicated the stage 3 findings in a dataset from 23andMe.

To investigate sex-specific loci for POAG, we also conducted a meta-analysis of POAG in males and females separately. For this analysis, we had GWAS data from a subset of the overall POAG meta-analysis, including 10,775 cases and 123,644 controls for males, and 10,977 cases and 144,606 controls for females (Supplementary Data 1). Similarly, to identify risk loci for the HTG and NTG subtypes, we performed a subtype-specific meta-analysis using 3247 NTG cases and 47,997 controls, and 5144 HTG cases and 47,997 controls.

Quality control (QC) and imputation. Study-specific QC and imputation details have been provided in Supplementary Information. Overall, SNPs with $>5\%$ missing genotypes, minor allele frequency (MAF) < 0.01 , and evidence of significant deviations from Hardy–Weinberg equilibrium (HWE) were excluded. In addition, individuals with $>5\%$ missing genotypes, one of each pair of related individuals (detected based on a $\hat{p} > 0.2$ from identity by descent calculated from autosomal markers), and ancestry outliers from each study (detected based on principal component analysis including study participants and reference samples of known ancestry) were excluded from further analysis (for more details please see Supplementary Information).

Imputation for studies involving participants of European descent was performed in Minimac3 using the Haplotype Reference Consortium (HRC) r1.1 as reference panel through the Michigan Imputation Server⁶⁶. However, for a study of Finnish population (FinnGen study), whole-genome sequence data from 3775 Finnish samples were used as reference panel for better population-specific haplotype matching, which results in a more accurate imputation. For studies involving Asian and African participants, imputation was performed using the 1000 Genomes samples of relevant ancestry. SNPs with MAF > 0.001 and imputation quality scores (INFO or r^2) > 0.3 were taken forward for association analysis.

Association testing. Association testing was performed assuming an additive genetic model using dosage scores from imputation, adjusting for age, sex, and study-specific principal components as covariates, using software such as

PLINK2^{66,67}, SNPTEST v2.5.1^{68,69}, SAIGE v0.36.3⁷⁰, EPACTS v3.2.6 (<https://genome.sph.umich.edu/wiki/EPACTS>), and Rvtest v2.0.3⁷¹. For studies with a large number of related individuals, mixed-model association testing was performed to account for relatedness between people. For the X chromosome analysis, we used the following approach to allow for dosage compensation: females were coded as 0 (homozygous for non-effect allele), 1 (heterozygous), and 2 (homozygous for effect allele) while males were coded as 0 (no effect allele) and 2 (one effect allele). The covariates were the same as for the association testing for the autosomes except removing sex.

To confirm the validity of combining GWAS results across populations comprising different ancestries, we estimated the genome-wide genetic correlation for POAG between the populations of European, Asian, and African descent participating in this study. For this purpose, we used Popcorn v0.9.9²¹, a toolset that provides estimates of genetic correlation while accounting for different genetic effects and LD structure between ancestries. For this analysis, the LD scores for each ancestry population were estimated using the 1000G populations (Europeans, Asians, and Africans), and SNPs were filtered based on the default MAF = 0.05 in Popcorn.

We performed within and between ancestry meta-analyses using a fixed-effects inverse-variance weighting approach in METAL (the version released on 2011-03-25)⁷² using SNP effect point estimates and their standard errors. The presence of heterogeneity between SNP effect estimates across studies were investigated using the Cochran's Q test implemented in METAL. To identify multiple independent risk variants within the same locus using GWAS summary statistics obtained from the meta-analysis, we used the Conditional and Joint (COJO) analysis implemented in GCTA v1.26⁷³. Q-Q and Manhattan plots were created in R-3.2.2, and regional association plots in LocusZoom v1.4⁷⁴.

We used the univariate LD score regression¹⁹ intercept for each study separately as well as for the meta-analyzed results to ensure that the test statistics did not include model or structural biases such as population stratification, cryptic relatedness, and model misspecification. To investigate the genetic correlation between POAG and AD, we used bivariate LD score regression³² using two large AD GWAS meta-analyses^{30,31}. To investigate the genetic correlation between POAG and the other traits, we used bivariate LD score regression through the LD Hub platform (<http://ldsc.broadinstitute.org/ldhub/>).

The association of the POAG risk loci identified in this study with its major endophenotypes, IOP and VCDR, was investigated using summary statistics from a recent GWAS meta-analysis for IOP ($N = 133,492$)¹¹ and VCDR ($N = 90,939$)¹⁵.

The variance in the POAG familial risk explained by the loci identified in this study ($N = 127$) was calculated based on $\sum_i 2p_i(1-p_i)\beta_i^2/\log(\lambda P)$, where p_i and β_i refer to the MAF and the magnitude of association of the i -th SNP, respectively, and $\log(\lambda P)$ is the familial relative risk obtained from observational studies. The estimates for p_i and β_i in this study were obtained from UKBB and European POAG meta-analysis, respectively, and $\log(\lambda P)$ was 9.2 estimated in a previous study⁷⁵.

23andMe replication. We validated the genome-wide significant risk loci from our cross-ancestry meta-analysis (127 independent SNPs) and subtype analyses (7 independent SNPs) in a subset of 23andMe research participants of European descent comprising 43,254 POAG cases and 1,471,118 controls. POAG cases were defined as those who reported glaucoma, excluding those who reported angle-closure glaucoma or other types of glaucoma. Controls did not report any glaucoma. Association testing was performed using logistic regression assuming an additive genetic model, adjusting for age, sex, top five principal components, and genotyping platform as covariates.

Cross-ancestry fine-mapping. We used PAINTOR v3.0^{76,77} to perform a cross-ancestry fine-mapping for the 127 risk loci identified in this study. For this analysis, the GWAS summary statistics for 1 Mb either side of the lead risk SNPs were extracted from European (including UKBB self-reports), Asian, and African meta-analyses, separately. To account for different LD patterns between ancestries, we created ancestry-specific LD matrices between SNPs using 1000G phase 3 as a reference panel. We allowed for the presence of two causal SNPs per locus. To investigate any advantage of fine-mapping across ancestries, we compared the posterior probabilities of the prioritized causal SNPs in Europeans separately, as well as across ancestries, without including any annotation data.

Gene-based and pathway-based tests. Gene-based and gene-set (pathway) based tests were performed using the approach implemented in MAGMA v1.07b³³. We performed this analysis for each ancestry separately, and the P -values were then combined across ancestries using Fisher's combined probability test. The significance threshold for gene-based test was set to $P < 0.05/20174$, and for pathway-based tests to $P < 0.05/10678$, accounting for the maximum number of independent genes/pathways tested. In addition, MAGMA was used to investigate the enrichment of the expression of the significant risk genes in GETX v6 tissues ($P < 1e-03$ accounting for 53 tissues tested).

To identify loci with effect on POAG risk due to modulation of gene expression, we also used alternative gene-based tests that integrate GWAS summary statistics with eQTL data throughout the genome (TWAS-based approaches). For this purpose, we used MetaXcan v0.3.3³⁸, SMR v0.69³⁷, and FOCUS v0.5⁴⁰. MetaXcan uses GWAS summary statistics to impute the genetic component of gene

expression in different tissues based on a reference eQTL panel. We used the EyeGEx eQTL data from retina³⁹, as well as 44 GTEx tissues as reference eQTL data for this study. The GWAS input for this analysis included the summary statistics obtained from the cross-ancestry meta-analysis. We set the significance threshold to Bonferroni-corrected $P < 1.5 \times 10^{-7}$, accounting for the maximum number of genes tested ($N = 7209$) in 45 tissues. To investigate the probability of each gene causally driving TWAS associations, we used the approach implemented in FOCUS⁴⁰, a probabilistic framework that assigns a posterior probability to each gene. We used the gene expression reference weights provided in FOCUS, which combines the expression weights obtained from GTEx tissues with the weights provided in FUSION⁷⁸ obtained from several tissues, including adipose, peripheral blood, whole blood, and brain.

SMR uses a Mendelian Randomization framework to identify genes whose expression is likely modulated through the same variants associated with the outcome of interest (POAG). For the SMR analysis, we used the following eQTL data: CAGE eQTL summary data from blood ($N = 2765$) and EyeGEx eQTL data from retina ($N = 406$). The SMR significance threshold was set to $P < 2.9 \times 10^{-6}$, accounting for the maximum number of 8516 genes tested in two tissues. A heterogeneity $P > 0.05$ from the HEIDI test implemented in SMR implies that we cannot reject the null hypothesis that a single causal variant is likely to affect both gene expression and POAG risk for these loci.

Gene expression. RNA was extracted from the corneal layers, trabecular meshwork, ciliary body, retina, and optic nerve tissues from 21 healthy donor eyes of 21 individuals. After quality control, the RNA was sequenced using Illumina NextSeq[®] 500 (San Diego, USA). Trimgalore (v0.4.0) was used to trim low-quality bases (Phred score < 28) and reads shorter than 20 bases after trimming were discarded. Data analysis was done with edgeR (version 3.22.5)⁷⁹. Only genes expressed a minimum of 10 times (1.5 counts per million) in at least five dissected tissues were kept. The RNA count libraries were normalized using trimmed mean of M -values method⁸⁰. Two-group differential expression analysis was done via negative binomial generalized linear model in edgeR⁸¹. The RNA expression in ciliary body, trabecular meshwork, and optic nerve head, which are involved in aqueous production, drainage and principal site of glaucoma injury, respectively, was compared to the remaining eye tissues.

Drug targets. We used Open Targets⁸² to search for drugs currently in use or in clinical trials for treating other ocular or systemic diseases that target the POAG risk genes identified in this study. These drugs can be potentially repurposed as alternative treatments for POAG, owing to in vivo and in vitro confirmation of the functionality of the target genes in the pathogenesis of POAG.

Bioinformatic functional analyses. The bioinformatic functional analysis to investigate the functional relevance of the identified risk loci for POAG were performed through the FUMA platform v1.3.5⁸³ using the following dataset/toolsets: GTEx eQTL v6⁸⁴, Blood eQTL browser⁸⁵, BIOS QTL Browser⁸⁶, BRAINEAC⁸⁷, RegulomeDB v1.1³⁶, CADD v1.4³⁵, ANNOVAR (the version released on 2016Feb01)⁸⁸, and Hi-C data from 21 tissue/cell types (GEO accession: GSE87112)⁸⁹, PsychENCODE⁹⁰, Giusti-Rodriguez et al. (2019)⁹¹, and FANTOM5 Human Enhancer Tracks (http://slidebase.binf.ku.dk/human_enhancers/presets).

Colocalization analysis. To test whether the POAG loci tag a shared causal variant or haplotype with Alzheimer's disease (AD), given that several loci overlap, we applied the bayesian-based colocalization method, eCAVIAR v2.0.0²⁹ to all 123 and 66 autosomal POAG significant variants from the cross-ancestry and European subset POAG GWAS meta-analyses, respectively, and the AD GWAS meta-analysis from Kunkle et al.^{30,31} and Jansen et al.³¹ that lack summary statistics for chromosome X. Loci were defined by identifying the outermost variant on either side of each lead POAG variant corresponding to $r^2 > 0.1$ relative to the POAG variant with an added 50 kb on either side. We used the default parameters of eCAVIAR (<http://genetics.cs.ucla.edu/caviar/manual.html>), assuming up to two causal variants per locus. We used the European derived samples from 1000 Genome Project Phase 3 as the reference panel to compute the LD matrix between all variant pairs within each locus needed in eCAVIAR, since both AD GWAS meta-analyses consisted of samples from European ancestry. We used a colocalization posterior probability (CLPP) above 0.01 as the significance cutoff as recommended by the tool²⁹.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The GWAS summary statistics generated in this study are available via GWAS Catalog under study accession identifiers GCST90011766, GCST90011767, GCST90011768, GCST90011769, GCST90011770. UK Biobank data, including POAG, VCDR, IOP, RNFL, and GCIPL GWASs are available by request through the UK Biobank Access Management System <https://www.ukbiobank.ac.uk/>. The GWAS result from 23andMe are available by request from <https://www.23andme.com/>. Restrictions apply to the

availability of these data (please see <https://www.ukbiobank.ac.uk/principles-of-access/> and <https://research.23andme.com/dataset-access/>), which were used under license for the current study, and so are not publicly available. The GWAS results for Alzheimer's disease that we used for this study are available from https://ctg.cncr.nl/software/summary_statistics, and by request from <https://www.niagads.org/datasets/ng00075>. The Haplotype Reference Consortium (HRC) r1.1 is accessible by request from <https://www.ebi.ac.uk/ega/studies/EGAS00001001710>. Data access requests are reviewed by the Data Access Committee at Wellcome Trust Sanger Institute. This resource can be used for imputation without direct access to the raw data through Michigan Imputation server (<https://imputationserver.sph.umich.edu/index.html#!>) and Sanger Imputation Service (<https://imputation.sanger.ac.uk/>). We used HRC r1.1 for imputation through the Michigan Imputation server. The 1000 Genomes phase 3 data is available at <https://www.internationalgenome.org/>. The datasets we used for the functional analyses in this study are available through: GTEx eQTL v6 (<https://gtexportal.org/home/>), Blood eQTL, BIOS QTL, EyeGEx data (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE115828>), BRAINEAC, Hi-C data from 21 tissue/cell types under GEO accession GSE87112, PsychENCODE, Giusti-Rodriguez et al. (2019) (<https://www.biorxiv.org/content/10.1101/406330v2>), and FANTOM5 Human Enhancer Tracks http://slidebase.binf.ku.dk/human_enhancers/presets. These datasets were used through the FUMA platform (<https://fuma.ctglab.nl/>). The drug target data was obtained through the Open Targets platform (<https://genetics.opentargets.org/>).

Received: 22 January 2020; Accepted: 8 December 2020;

Published online: 24 February 2021

References

- Quigley, H. A. The number of people with glaucoma worldwide in 2010 and 2020. *Br. J. Ophthalmol.* **90**, 262–267 (2006).
- Jonas, J. B. et al. Glaucoma. *Lancet* **390**, 2183–2193 (2017).
- Tham, Y.-C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. *Ophthalmology* **121**, 2081–2090 (2014).
- Cuellar-Partida, G. et al. Assessment of polygenic effects links primary open-angle glaucoma and age-related macular degeneration. *Sci. Rep.* **6**, 26885 (2016).
- Wang, K., Gaitsch, H., Poon, H., Cox, N. J. & Rzhetsky, A. Classification of common human diseases derived from shared genetic and environmental determinants. *Nat. Genet.* **49**, 1319–1325 (2017).
- Gharahkhani, P. et al. Common variants near ABCA1, AFAP1 and GMDS confer risk of primary open-angle glaucoma. *Nat. Genet.* **46**, 1120–1125 (2014).
- Bailey, J. N. C. et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. *Nat. Genet.* **48**, 189–194 (2016).
- Choquet, H. et al. A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. *Soc. Commun.* **9**, 2278 (2018).
- Shiga, Y. et al. Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. *Hum. Mol. Genet.* **27**, 1486–1496 (2018).
- Khawaja, A. P. et al. Genome-wide analyses identify 68 new loci associated with intraocular pressure and improve risk prediction for primary open-angle glaucoma. *Nat. Genet.* **50**, 778–782 (2018).
- MacGregor, S. et al. Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. *Nat. Genet.* **50**, 1067–1071 (2018).
- Choquet, H., Wiggs, J. L. & Khawaja, A. P. Clinical implications of recent advances in primary open-angle glaucoma genetics. *Eye* <https://doi.org/10.1038/s41433-019-0632-7> (2019).
- Choquet, H. et al. A large multi-ethnic genome-wide association study identifies novel genetic loci for intraocular pressure. *Nat. Commun.* **8**, 2108 (2017).
- Gharahkhani, P. et al. Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma. *Sci. Rep.* **8**, 3124 (2018).
- Craig, J. E. et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat. Genet.* **52**, 160–166 (2020).
- Kapetanakis, V. V. et al. Global variations and time trends in the prevalence of primary open angle glaucoma (POAG): a systematic review and meta-analysis. *Br. J. Ophthalmol.* **100**, 86–93 (2016).
- Quigley, H. A. et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. *Arch. Ophthalmol.* **119**, 1819–1826 (2001).
- Stein, J. D. et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. *Ophthalmology* **118**, 1031–1037 (2011).
- Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).

20. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
21. Brown, B. C., Asian Genetic Epidemiology Network Type 2 Diabetes Consortium, Ye, C. J., Price, A. L. & Zaitlen, N. Transethnic genetic-correlation estimates from summary statistics. *Am. J. Hum. Genet.* **99**, 76–88 (2016).
22. Gharahkhani, P. et al. Accurate imputation-based screening of Gln368Ter myocilin variant in primary open-angle glaucoma. *Invest. Ophthalmol. Vis. Sci.* **56**, 5087–5093 (2015).
23. Stone, E. M. et al. Identification of a gene that causes primary open angle glaucoma. *Science* **275**, 668–670 (1997).
24. Shin, J. W., Sung, K. R. & Song, M. K. Ganglion cell-inner plexiform layer and retinal nerve fiber layer changes in glaucoma suspects enable prediction of glaucoma development. *Am. J. Ophthalmol.* **210**, 26–34 (2020).
25. Laville, V. et al. Genetic correlations between diabetes and glaucoma: an analysis of continuous and dichotomous phenotypes. *Am. J. Ophthalmol.* **206**, 245–255 (2019).
26. Zhou, F. & Wang, D. The associations between the MAPT polymorphisms and Alzheimer's disease risk: a meta-analysis. *Oncotarget* **8**, 43506–43520 (2017).
27. Jun, G. et al. A novel Alzheimer disease locus located near the gene encoding tau protein. *Mol. Psychiatry* **21**, 108–117 (2016).
28. Hardy, J. The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the 'amyloid cascade hypothesis'. *FEBS J.* **284**, 1040–1044 (2017).
29. Hormozdiari, F. et al. Colocalization of GWAS and eQTL signals detects target genes. *Am. J. Hum. Genet.* **99**, 1245–1260 (2016).
30. Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat. Genet.* **51**, 414–430 (2019).
31. Jansen, I. E. et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat. Genet.* **51**, 404–413 (2019).
32. Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. *Nat. Genet.* **47**, 1236–1241 (2015).
33. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput. Biol.* **11**, e1004219 (2015).
34. Fisher, R. A. *Statistical Methods For Research Workers*. (Genesis Publishing Pvt Ltd, 1925).
35. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat. Genet.* **46**, 310–315 (2014).
36. Boyle, A. P. et al. Annotation of functional variation in personal genomes using RegulomeDB. *Genome Res.* **22**, 1790–1797 (2012).
37. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
38. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
39. Ratnapriya, R. et al. Retinal transcriptome and eQTL analyses identify genes associated with age-related macular degeneration. *Nat. Genet.* **51**, 606–610 (2019).
40. Mancuso, N. et al. Probabilistic fine-mapping of transcriptome-wide association studies. *Nat. Genet.* **51**, 675–682 (2019).
41. Springelkamp, H. et al. New insights into the genetics of primary open-angle glaucoma based on meta-analyses of intraocular pressure and optic disc characteristics. *Hum. Mol. Genet.* **26**, 438–453 (2017).
42. Liu, Y. et al. Investigation of known genetic risk factors for primary open angle glaucoma in two populations of African ancestry. *Invest. Ophthalmol. Vis. Sci.* **54**, 6248–6254 (2013).
43. Poveda, J. et al. MXRA5 is a TGF- β 1-regulated human protein with anti-inflammatory and anti-fibrotic properties. *J. Cell. Mol. Med.* **21**, 154–164 (2017).
44. Kaminska, B. & Cyranski, S. Recent advances in understanding mechanisms of TGF beta signaling and its role in glioma pathogenesis. *Adv. Exp. Med. Biol.* **1202**, 179–201 (2020).
45. Kaufman, P. L. Deconstructing aqueous humor outflow - The last 50 years. *Exp. Eye Res.* **197**, 108105 (2020).
46. Morooka, N. et al. Polydom is an extracellular matrix protein involved in lymphatic vessel remodeling. *Circ. Res.* **120**, 1276–1288 (2017).
47. Kizhatil, K., Ryan, M., Marchant, J. K., Henrich, S. & John, S. W. M. Schlemm's canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process. *PLoS Biol.* **12**, e1001912 (2014).
48. Park, D.-Y. et al. Lymphatic regulator PROX1 determines Schlemm's canal integrity and identity. *J. Clin. Invest.* **124**, 3960–3974 (2014).
49. Souma, T. et al. Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity. *J. Clin. Invest.* **126**, 2575–2587 (2016).
50. Thomson, B. R. et al. Angiopoietin-1 is required for Schlemm's canal development in mice and humans. *J. Clin. Invest.* **127**, 4421–4436 (2017).
51. Young, T. L. et al. SVEP1 as a genetic modifier of TEK-related primary congenital glaucoma. *Invest. Ophthalmol. Vis. Sci.* **61**, 6 (2020).
52. Staverosky, J., Dhamodaran, K., Acott, T., Raghunathan, V. & Vranka, J. Isolation and characterization of primary human trabecular meshwork cells from segmental flow regions: New tools for understanding segmental flow. *Exp. Eye Res.* **197**, 108046 (2020).
53. Fregeau, B. et al. De novo mutations of RERE cause a genetic syndrome with features that overlap those associated with proximal 1p36 deletions. *Am. J. Hum. Genet.* **98**, 963–970 (2016).
54. Carnes, M. U. et al. Discovery and functional annotation of SIX6 variants in primary open-angle glaucoma. *PLoS Genet.* **10**, e1004372 (2014).
55. Axenovich, T. et al. Linkage and association analyses of glaucoma related traits in a large pedigree from a Dutch genetically isolated population. *J. Med. Genet.* **48**, 802–809 (2011).
56. Gururaja Rao, S., Patel, N. J. & Singh, H. Intracellular chloride channels: novel biomarkers in diseases. *Front. Physiol.* **11**, 96 (2020).
57. Meruvu, S., Hugendubler, L. & Mueller, E. Regulation of adipocyte differentiation by the zinc finger protein ZNF638. *J. Biol. Chem.* **286**, 26516–26523 (2011).
58. Lin, Y.-J. et al. Association of human height-related genetic variants with familial short stature in Han Chinese in Taiwan. *Sci. Rep.* **7**, 6372 (2017).
59. Wood, I. S., Hunter, L. & Trayhurn, P. Expression of Class III facilitative glucose transporter genes (GLUT-10 and GLUT-12) in mouse and human adipose tissues. *Biochem. Biophys. Res. Commun.* **308**, 43–49 (2003).
60. Lee, M., Goraya, N., Kim, S. & Cho, S.-H. Hippo-yap signaling in ocular development and disease. *Dev. Dyn.* **247**, 794–806 (2018).
61. Kim, S. et al. Ocular phenotypic consequences of a single copy deletion of the gene *()* in mice. *Mol. Vis.* **25**, 129–142 (2019).
62. Aerts, F. et al. Mechanism of inactivation of occludin in porcine vitreous. *Biophys. Chem.* **165–166**, 30–38 (2012).
63. Nascimento E Silva, R. et al. Microvasculature of the optic nerve head and peripapillary region in patients with primary open-angle glaucoma. *J. Glaucoma* **28**, 281–288 (2019).
64. Cousins, C. C. et al. Resting nailfold capillary blood flow in primary open-angle glaucoma. *Br. J. Ophthalmol.* **103**, 203–207 (2019).
65. Chan, M. P. Y. et al. Glaucoma and intraocular pressure in EPIC-Norfolk Eye Study: cross sectional study. *BMJ* **358**, j3889 (2017).
66. Das, S. et al. Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).
67. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am. J. Hum. Genet.* **81**, 559–575 (2007).
68. Marchini, J. & Howie, B. Genotype imputation for genome-wide association studies. *Nat. Rev. Genet.* **11**, 499–511 (2010).
69. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* **447**, 661–678 (2007).
70. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
71. Zhan, X., Hu, Y., Li, B., Abecasis, G. R. & Liu, D. J. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423–1426 (2016).
72. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).
73. Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**(369–75), S1–3 (2012).
74. Pruim, R. J. et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336–2337 (2010).
75. Wolfs, R. C. et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. *Arch. Ophthalmol.* **116**, 1640–1645 (1998).
76. Kichaev, G. et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *PLoS Genet.* **10**, e1004722 (2014).
77. Kichaev, G. & Pasaniuc, B. Leveraging functional-annotation data in trans-ethnic fine-mapping studies. *Am. J. Hum. Genet.* **97**, 260–271 (2015).
78. Gusev, A. et al. Integrative approaches for large-scale transcriptome-wide association studies. *Nat. Genet.* **48**, 245–252 (2016).
79. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).
80. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
81. McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res.* **40**, 4288–4297 (2012).

82. Koscielny, G. et al. Open Targets: a platform for therapeutic target identification and validation. *Nucleic Acids Res.* **45**, D985–D994 (2017).
83. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
84. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648–660 (2015).
85. Westra, H.-J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat. Genet.* **45**, 1238–1243 (2013).
86. Zhernakova, D. V. et al. Identification of context-dependent expression quantitative trait loci in whole blood. *Nat. Genet.* **49**, 139–145 (2017).
87. Ramasamy, A. et al. Genetic variability in the regulation of gene expression in ten regions of the human brain. *Nat. Neurosci.* **17**, 1418–1428 (2014).
88. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* **38**, e164 (2010).
89. Schmitt, A. D. et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. *Cell Rep.* **17**, 2042–2059 (2016).
90. Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human brain. *Science* **362**, eaat8464 (2018).
91. Giusti-Rodriguez, P. et al. Using three-dimensional regulatory chromatin interactions from adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. *Cold Spring Harbor Laboratory* 406330 <https://doi.org/10.1101/406330> (2019).

Acknowledgements

This work was conducted using the UK Biobank Resource (application number 25331) and publicly available data from the International Glaucoma Genetics Consortium. This work was also supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (#1107098; 1116360, 1116495, 1023911), the Ophthalmic Research Institute of Australia, the BrightFocus Foundation, UK and Eire Glaucoma Society and Charitable Funds from Royal Liverpool University Hospital, and International Glaucoma Association-Royal College of Ophthalmologists. P.G. is supported by a NHMRC Investigator Grant (#1173390). S.M., J.E.C., K.P.B., and A.W.H. are supported by NHMRC Fellowships. A.P.K. was funded by a Moorfields Eye Charity Career Development Fellowship, a UK Research and Innovation Future Leaders Fellowship and an Alcon Research Institute Young Investigator Award. The EPIC-Norfolk study has received funding from the Medical Research Council (MR/N003284/1, MC-UU_12015/1, and MC_PC_13048) and Cancer Research UK (C864/A14136). The NEIGHBORHOOD consortium is supported by NIH grants P30 EY014104, R01 EY015473, and R01 EY022305. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech Inc). This work was also supported by the National Eye Institute/National Institutes of Health [R01EY018246, and support from the National Institutes of Health Center for Inherited Disease Research to T.L.Y.]; a University of Wisconsin Centennial Scholars Award [to T.L.Y.]; and an unrestricted grant from Research to Prevent Blindness, Inc. to the UW-Madison Department of Ophthalmology and Visual Sciences [to T.L.Y.]. Additional acknowledgments are supplied in the Supplementary Information file.

Author contributions

P.G., E.J., P.H., A.P.K., S.P., A.W.H., R.P.J.I., H.C., J.N.C.B., P.B., T.L.Y., V.V., A.H.J.T., J.K., R.B.M., K.S.N., R.L., M.S., N.A., A.J.C., R.H., A.P., L.J.C., C.C., E.N.V., G.T., Y.S., M.Y., T.N., J.R., E.B., M.K.L., N.G.M., O.O., K.H., Y.K., M.A., Y.M., P.J.F., P.T.K., J.E.M., N.G.S., P.K., J.H.K., C.C.P., F.P., P.M., A.J.L., A.P., C.v.D., J.H., C.H., A.A., S.O., S.A., S.W., M.R., L.R.P., C.C.K., M.H., C.K., D.A.M., M.K., T.A., J.C., S.M., and J.W. were involved in data collection and contributed to genotyping. P.G., P.H., X.H., J.S.O., A.V.S., R.P.J.I., H.C., A.Q., N.S.J., J.M.R., A.R.H., P.B., A.I., J.K., S.U., S.S.R., M.S., G.T., H.C., X.W., A.A., M.A., and J.H.K. were involved in data analysis. P.G., S.M., and J.W. wrote the first draft of the paper. E.J., A.P.K., P.J.F., P.T.K., A.J.L., A.P., M.H., C.C.K., D.A.M., M.K., T.A., J.C., S.M., and J.W. designed the study and obtained the funding.

Competing interests

X.W. and A.A. are employed by and hold stock or stock options in 23andMe, Inc. J.W. is a consultant for Allergan, Editas, Maze, Regenxbio and has received sponsored research support from Aerpio Pharmaceuticals Inc. L.P. is a consultant for Eyeovia, Bausch + Lomb, Verily, and Nicox. T.L.Y. serves as a consultant to Aerpio Pharmaceuticals, Inc. A.P.K. is a consultant to Aerie, Allergan, Google Health, Novartis, Reichert, Santen and Thea. All remaining authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-020-20851-4>.

Correspondence and requests for materials should be addressed to P.G.

Peer review information *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021

¹QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. ²Division of Research, Kaiser Permanente Northern California (KPNC), Oakland, CA, USA. ³Twin Research and Genetic Epidemiology, King's College London, London, UK. ⁴NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK. ⁵Department of Public Health and Primary Care, Institute of Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK. ⁶Geisinger Research, Biomedical and Translational Informatics Institute, Danville, PA, USA. ⁷Menzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia. ⁸Centre for Eye Research Australia, University of Melbourne, Melbourne, VIC, Australia. ⁹Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. ¹⁰Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ¹¹Department of Ophthalmology, Flinders University, Bedford Park, SA, Australia. ¹²Geisinger Research, Biomedical and Translational Informatics Institute, Rockville, MD, USA. ¹³Cleveland Institute for Computational Biology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ¹⁴Department of Ophthalmology, Erasmus MC, Rotterdam, The Netherlands. ¹⁵Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands. ¹⁶The Rotterdam Eye Hospital, Rotterdam, The Netherlands. ¹⁷Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands. ¹⁸Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI, USA. ¹⁹Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK. ²⁰Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Helsinki, Finland. ²¹Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. ²²Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ²³Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität, Erlangen-Nürnberg, Erlangen, Germany. ²⁴Department of Ophthalmology, KPNC, Redwood City, CA, USA. ²⁵Department of Ophthalmology, School of Medicine, University of California San Francisco (UCSF), San Francisco, CA, USA. ²⁶Department of Ophthalmology, Kings College London, London, United Kingdom.

²⁷Institute of Ophthalmology, University College London, London, UK. ²⁸University Hospital Southampton NHS Foundation Trust, Southampton, UK. ²⁹Faculty of Medicine, University of Southampton, Southampton, UK. ³⁰Department of Ophthalmology, Inselspital, University Hospital Bern, University of Bern, Bern, Germany. ³¹Department of Ophthalmology, University Medical Center Mainz, Mainz, Germany. ³²Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center Mainz, Mainz, Germany. ³³Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China. ³⁴Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore. ³⁵Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore. ³⁶Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ³⁷Duke-National University of Singapore Medical School, Singapore, Republic of Singapore. ³⁸Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi, Japan. ³⁹RIKEN Center for Advanced Intelligence Project, 1-4-1 Nihonbashi, Chuo-ku, Tokyo, Japan. ⁴⁰Department of Ophthalmology, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Miyagi, Japan. ⁴¹Department of Retinal Disease Control, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Miyagi, Japan. ⁴²Department of Advanced Ophthalmic Medicine, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Miyagi, Japan. ⁴³Department of Ophthalmic Imaging and Information Analytics, Tohoku University Graduate School of Medicine, 1-1, Seiryomachi, Aoba-ku, Sendai, Miyagi, Japan. ⁴⁴European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, UK. ⁴⁵23 and Me Inc., San Francisco, CA, USA. ⁴⁶Department of Ophthalmology, University of Ibadan, Ibadan, Nigeria. ⁴⁷Division of Ophthalmology, Department of Neurosciences, University of the Witwatersrand, Johannesburg, South Africa. ⁴⁸Unit of Ophthalmology, Department of Surgery, University of Ghana Medical School, Accra, Ghana. ⁴⁹Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. ⁵⁰Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁵¹Laboratory of Complex Trait Genomics, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ⁵²Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ⁵³Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁵⁴National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust & UCL Institute of Ophthalmology, London, UK. ⁵⁵UCL Institute of Ophthalmology, University College London, London, UK. ⁵⁶Cardiff Centre for Vision Sciences, College of Biomedical and Life Sciences, Maindy Road, Cardiff University, Cardiff, UK. ⁵⁷Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ⁵⁸Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ⁵⁹Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China. ⁶⁰Centre for Vision Research, Department of Ophthalmology and Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia. ⁶¹Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland. ⁶²Psychiatric & Neurodevelopmental Genetics Unit, Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, USA. ⁶³Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶⁴Nuffield Department of Population Health, University of Oxford, Oxford, UK. ⁶⁵Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ⁶⁶Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands. ⁶⁷Institute for Molecular and Clinical Ophthalmology, Basel, Switzerland. ⁶⁸Department of Medicine, Duke University, Durham, NC, USA. ⁶⁹Department of Ophthalmology, Duke University, Durham, NC, USA. ⁷⁰Singapore Eye Research Institute, Singapore, Singapore. ⁷¹Duke-NUS Medical School, Singapore, Singapore. ⁷²Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore. ⁷³Centre for Ophthalmology and Visual Science, University of Western Australia, Lions Eye Institute, Nedlands, WA, Australia. ⁷⁴RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ⁷⁵Department of Ophthalmology, Flinders University, Flinders Medical Centre, Bedford Park, SA, Australia. ¹⁹⁰These authors contributed equally: Puya Gharahkhani, Eric Jorgenson, Pirro Hysi, Anthony P. Khawaja, Sarah Pendergrass. ¹⁹¹These authors jointly supervised this work: Michiaki Kubo, Ching-Yu Cheng, Jamie E. Craig, Stuart MacGregor, Janey L. Wiggs. *Lists of authors and their affiliations appear at the end of the paper. [✉]email: Puya.Gharahkhani@qimrberghofer.edu.au

NEIGHBORHOOD consortium

R. Rand Allingham⁷⁶, Murray Brilliant⁷⁷, Donald L. Budenz⁷⁸, Jessica N. Cooke Bailey¹⁰, John H. Finger⁷⁹, Douglas Gaasterland⁸⁰, Teresa Gaasterland⁸¹, Jonathan L. Haines¹⁰, Michael Hauser⁶⁸, Robert P. Igo Jr¹⁰, Jae Hee Kang⁵⁸, Peter Kraft⁵⁷, Richard K. Lee⁸², Paul R. Lichter⁸³, Yutao Liu^{84,85}, Louis R. Pasquale⁶⁵ & Syoko Moroi⁸³, Jonathan Myers⁸⁶, Margaret Pericak-Vance⁸⁷, Anthony Realini⁸⁸, Doug Rhee⁸⁹, Julia E. Richards⁸³, Robert Ritch⁹⁰, Joel S. Schuman⁹¹, William K. Scott⁸⁷, Kuldev Singh⁹², Arthur J. Sit⁹³, Douglas Vollrath⁹⁴, Robert N. Weinreb⁹⁵, Janey L. Wiggs^{9,191}, Gadi Wollstein⁹¹ & Donald J. Zack⁹⁶

⁷⁶Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA. ⁷⁷Center for Human Genetics, Marshfield Clinic Research Foundation, Marshfield, WI, USA. ⁷⁸Department of Ophthalmology, University of North Carolina, Chapel Hill, NC, USA. ⁷⁹Department of Ophthalmology, University of Iowa, College of Medicine, Iowa City, IA, USA. ⁸⁰Eye Doctors of Washington, Chevy Chase, MD, USA. ⁸¹Scripps Genome Center, University of California at San Diego, San Diego, CA, USA. ⁸²Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA. ⁸³Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA. ⁸⁴Department of Cellular Biology and Anatomy, Georgia Regents University, Augusta, Georgia, USA. ⁸⁵James and Jean Culver Vision Discovery Institute, Georgia Regents University, Augusta, GA, USA. ⁸⁶Wills Eye Hospital, Philadelphia, PA, USA. ⁸⁷Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, FL, USA. ⁸⁸Department of Ophthalmology, West Virginia University Eye Institute, Morgantown, WV, USA. ⁸⁹Department of Ophthalmology, Case Western Reserve University School of Medicine, Cleveland, OH, USA. ⁹⁰Einhorn Clinical Research Center, Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai, New York, NY, USA. ⁹¹Department of Ophthalmology, NYU School of Medicine, New York, NY, USA. ⁹²Department of Ophthalmology, Stanford University School of Medicine, Palo Alto, CA, USA. ⁹³Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA. ⁹⁴Department of Genetics, Stanford University School of Medicine, Palo Alto, CA, USA. ⁹⁵Hamilton Glaucoma Center, Shiley Eye Institute, University of California, San Diego, CA, USA. ⁹⁶Wilmer Eye Institute, Johns Hopkins University Hospital, Baltimore, MD, USA.

ANZRAG consortium

Shiwani Sharma⁷⁵, Sarah Martin⁷⁵, Tiger Zhou⁷⁵, Emmanuelle Souzeau⁷⁵, John Landers⁷⁵, Jude T. Fitzgerald⁷⁵, Richard A. Mills⁷⁵, Jamie Craig⁷⁵, Kathryn Burdon⁹⁷, Stuart L. Graham⁹⁸, Robert J. Casson⁹⁹, Ivan Goldberg¹⁰⁰, Andrew J. White⁶⁰, Paul R. Healey⁶⁰, David A. Mackey⁷³ & Alex W. Hewitt⁷

⁹⁷School of Medicine, Menzies Research Institute Tasmania, University of Tasmania, Hobart, TAS, Australia. ⁹⁸Ophthalmology and Vision Science, Macquarie University, Sydney, NSW, Australia. ⁹⁹South Australian Institute of Ophthalmology, University of Adelaide, Adelaide, SA, Australia. ¹⁰⁰Department of Ophthalmology, University of Sydney, Sydney Eye Hospital, Sydney, NSW, Australia.

Biobank Japan project

Masaki Shiono¹⁰¹, Kazuo Misumi¹⁰¹, Reiji Kaieda¹⁰¹, Hiromasa Harada¹⁰¹, Shiro Minami¹⁰², Mitsuru Emi¹⁰², Naoya Emoto¹⁰², Hiroyuki Daida¹⁰³, Katsumi Miyauchi¹⁰³, Akira Murakami¹⁰³, Satoshi Asai¹⁰⁴, Mitsuhiro Moriyama¹⁰⁴, Yasuo Takahashi¹⁰⁴, Tomoaki Fujioka¹⁰⁵, Wataru Obara¹⁰⁵, Seiji Mori¹⁰⁶, Hideki Ito¹⁰⁶, Satoshi Nagayama¹⁰⁷, Yoshio Miki¹⁰⁷, Akihito Masumoto¹⁰⁸, Akira Yamada¹⁰⁸, Yasuko Nishizawa¹⁰⁹, Ken Kodama¹⁰⁹, Hiromu Kutsumi¹¹⁰, Yoshihisa Sugimoto¹¹⁰, Yukihiko Koretsune¹¹¹, Hideo Kusuoka¹¹¹, Hideki Yanaig¹¹², Akiko Nagai¹¹³, Makoto Hirata¹¹⁴, Yoichiro Kamatani⁵⁰, Kaori Muto¹¹⁵, Koichi Matsuda^{116,117}, Yutaka Kiyohara¹¹⁸, Toshiharu Ninomiya¹¹⁹, Akiko Tamakoshi¹²⁰, Zentaro Yamagata¹²¹, Taisei Mushiroda¹²², Yoshinori Murakami¹²³, Koichiro Yuji¹²⁴, Yoichi Furukawa¹²⁵, Hitoshi Zembutsu^{116,126}, Toshihiro Tanaka^{127,128,129}, Yoza Ohnishi^{127,130}, Yusuke Nakamura^{116,131} Michiaki Kubo^{74,191}

¹⁰¹Tokushukai Hospitals, Okinawa, Japan. ¹⁰²Nippon Medical School, Tokyo, Japan. ¹⁰³Juntendo University, Tokyo, Japan. ¹⁰⁴Nihon University, Tokyo, Japan. ¹⁰⁵Iwate Medical University, Morioka, Japan. ¹⁰⁶Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. ¹⁰⁷The Cancer Institute Hospital of JFCR, Tokyo, Japan. ¹⁰⁸Aso Iizuka Hospital, Iizuka, Japan. ¹⁰⁹Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan. ¹¹⁰Shiga University of Medical Science, Otsu, Japan. ¹¹¹National Hospital Organization, Osaka National Hospital, Osaka, Japan. ¹¹²Fukujuji Hospital, Tokyo, Japan. ¹¹³Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹¹⁴Laboratory of Genome Technology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹¹⁵Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹¹⁶Laboratory of Molecular Medicine, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹¹⁷Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. ¹¹⁸Hisayama Research Institute for Lifestyle Diseases, Fukuoka, Japan. ¹¹⁹Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ¹²⁰Department of Public Health, Hokkaido University Graduate School of Medicine, Sapporo, Japan. ¹²¹Department of Health Sciences, University of Yamanashi, Yamanashi, Japan. ¹²²Laboratory for Pharmacogenomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan. ¹²³Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹²⁴Project Division of International Advanced Medical Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹²⁵Division of Clinical Genome Research, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ¹²⁶Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan. ¹²⁷SNP Research Center, RIKEN Yokohama Institute, Yokohama, Japan. ¹²⁸Department of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. ¹²⁹Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan. ¹³⁰Shinko Clinic, Medical Corporation Shinkokai, Tokyo, Japan. ¹³¹Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, USA.

FinnGen study

Anu Jalanko⁶¹, Jaakko Kaprio¹³², Kati Donner⁶¹, Mari Kaunisto⁶¹, Nina Mars⁶¹, Alexander Dada⁶¹, Anastasia Shcherban⁶¹, Andrea Ganna⁶¹, Arto Lehisto⁶¹, Elina Kilpeläinen⁶¹, Georg Brein⁶¹, Ghazal Awaisa⁶¹, Jarmo Harju⁶¹, Kalle Pärn⁶¹, Pietro Della Briotta Parolo⁶¹, Risto Kajanne⁶¹, Susanna Lemmelä⁶¹, Timo P. Sipilä⁶¹, Tuomas Sipilä⁶¹, Ulrike Lyhs⁶¹, Vincent Llorens⁶¹, Teemu Niiranen¹³³, Kati Kristiansson¹³⁴, Lotta Männikkö¹³⁴, Manuel González Jiménez¹³⁴, Markus Perola¹³⁴, Regis Wong¹³⁴, Terhi Kilpi¹³⁴, Tero Hiekkalinna¹³⁴, Elina Järvensivu¹³⁴, Essi Kaiharju¹³⁴, Hannele Mattsson¹³⁴, Markku Laukkanen¹³⁴, Päivi Laiho¹³⁴, Sini Lähteenmäki¹³⁴, Tuuli Sistonen¹³⁴, Sirpa Soini¹³⁴, Adam Ziemann¹³⁵, Anne Lehtonen¹³⁵, Apinya Lertratanaku¹³⁵, Bob Georgantas¹³⁵, Bridget Riley-Gillis¹³⁵, Danjuma Quarless¹³⁵, Fedik Rahimov¹³⁵, Graham Heap¹³⁵, Howard Jacob¹³⁵, Jeffrey Waring¹³⁵, Justin Wade Davis¹³⁵, Nizar Smaoui¹³⁵, Relja Popovic¹³⁵, Sahar Esmaeeli¹³⁵, Jeff Waring¹³⁵, Athena Matakidou¹³⁶, Ben Challis¹³⁶, David Close¹³⁶, Slavé Petrovski¹³⁶, Antti Karlsson¹³⁷, Johanna Schleutker¹³⁷, Kari Pulkki¹³⁷, Petri Virolainen¹³⁷, Lila Kallio¹³⁷, Arto Mannermaa¹³⁸,

Sami Heikkinen¹³⁸, Veli-Matti Kosma¹³⁸, Chia-Yen Chen¹³⁹, Heiko Runz¹³⁹, Jimmy Liu¹³⁹, Paola Bronson¹³⁹, Sally John¹³⁹, Sanni Lahdenperä¹³⁹, Susan Eaton¹³⁹, Wei Zhou¹⁴⁰, Minna Hendolin¹⁴¹, Outi Tuovila¹⁴¹, Raimo Pakkanen¹⁴¹, Joseph Maranville¹⁴², Keith Usiskin¹⁴², Marla Hochfeld¹⁴², Robert Plenge¹⁴², Robert Yang¹⁴², Shameek Biswas¹⁴², Steven Greenberg¹⁴², Eija Laakkonen¹⁴³, Juha Kononen¹⁴³, Juha Paloneva¹⁴³, Urho Kujala¹⁴³, Teijo Kuopio¹⁴³, Jari Laukkanen¹⁴³, Eeva Kangasniemi¹⁴⁴, Kimmo Savinainen¹⁴⁴, Reijo Laaksonen¹⁴⁴, Mikko Arvas¹⁴⁴, Jarmo Ritari¹⁴⁵, Jukka Partanen¹⁴⁴, Kati Hyvärinen¹⁴⁴, Tiina Wahlfors¹⁴⁴, Andrew Peterson¹⁴⁶, Danny Oh¹⁴⁶, Diana Chang¹⁴⁶, Edmond Teng¹⁴⁶, Erich Strauss¹⁴⁶, Geoff Kerchner¹⁴⁶, Hao Chen¹⁴⁶, Hubert Chen¹⁴⁶, Jennifer Schutzman¹⁴⁶, John Michon¹⁴⁶, Julie Hunkapiller¹⁴⁶, Mark McCarthy¹⁴⁶, Natalie Bowers¹⁴⁶, Tim Lu¹⁴⁶, Tushar Bhangale¹⁴⁶, David Pulford¹⁴⁷, Dawn Waterworth¹⁴⁷, Diptee Kulkarni¹⁴⁷, Fanli Xu¹⁴⁷, Jo Betts¹⁴⁷, Jorge Esparza Gordillo¹⁴⁷, Joshua Hoffman¹⁴⁷, Kirsi Auro¹⁴⁷, Linda McCarthy¹⁴⁷, Soumitra Ghosh¹⁴⁷, Meg Ehm¹⁴⁷, Kimmo Pitkänen¹⁴⁸, Tomi Mäkelä¹⁴⁹, Anu Loukola¹⁵⁰, Heikki Joensuu¹⁵⁰, Juha Sinisalo¹⁵⁰, Kari Eklund¹⁵⁰, Lauri Aaltonen¹⁵⁰, Martti Färkkilä¹⁵⁰, Olli Carpen¹⁵⁰, Paula Kauppi¹⁵⁰, Pentti Tienari¹⁵⁰, Terhi Ollila¹⁵⁰, Tiinamaija Tuomi¹⁵⁰, Tuomo Meretoja¹⁵⁰, Anne Pitkäranta¹⁵⁰, Joni Turunen¹⁵⁰, Katariina Hannula-Jouppi¹⁵⁰, Sampsa Pikkarainen¹⁵⁰, Sanna Seitsonen¹⁵⁰, Miika Koskinen¹⁵⁰, Antti Palomäki¹⁵¹, Juha Rinne¹⁵¹, Kaj Metsärinne¹⁵¹, Klaus Elenius¹⁵¹, Laura Pirilä¹⁵¹, Leena Koulu¹⁵¹, Markku Voutilainen¹⁵¹, Markus Juonala¹⁵¹, Sirkku Peltonen¹⁵¹, Vesa Aaltonen¹⁵¹, Andrey Loboda¹⁵², Anna Podgoraia¹⁵², Aparna Chhibber¹⁵², Audrey Chu¹⁵², Caroline Fox¹⁵², Dorothee Diogo¹⁵², Emily Holzinger¹⁵², John Eicher¹⁵², Padhraig Gormley¹⁵², Vinay Mehta¹⁵², Xulong Wang¹⁵², Johannes Kettunen¹⁵³, Katri Pylkäs¹⁵³, Marita Kalaoja¹⁵³, Minna Karjalainen¹⁵³, Reetta Hinttala¹⁵³, Riitta Kaarteenaho¹⁵³, Seppo Vainio¹⁵³, Tuomo Mantere¹⁵³, Anne Remes¹⁵⁴, Johanna Huhtakangas¹⁵⁴, Juhani Junttila¹⁵⁴, Kaisa Tasanen¹⁵⁴, Laura Huilaja¹⁵⁴, Marja Luodonpää¹⁵⁴, Nina Hautala¹⁵⁴, Peeter Karihtala¹⁵⁴, Saila Kauppila¹⁵⁴, Terttu Harju¹⁵⁴, Timo Blomster¹⁵⁴, Hilikka Soininen¹⁵⁵, Ilkka Harvima¹⁵⁵, Jussi Pihlajamäki¹⁵⁵, Kai Kaarniranta¹⁵⁵, Margit Pelkonen¹⁵⁵, Markku Laakso¹⁵⁵, Mikko Hiltunen¹⁵⁵, Mikko Kiviniemi¹⁵⁵, Oili Kaipiainen-Seppänen¹⁵⁵, Päivi Auvinen¹⁵⁵, Reetta Kälviäinen¹⁵⁵, Valtteri Julkunen¹⁵⁵, Anders Malarstig¹³², Åsa Hedman¹³², Catherine Marshall¹³², Christopher Whelan¹³², Heli Lehtonen¹³², Jaakko Parkkinen¹³², Kari Linden¹³², Kirsi Kalpala¹³², Melissa Miller¹³², Nan Bing¹³², Stefan McDonough¹³², Xing Chen¹³², Xinli Hu¹³², Ying Wu¹³², Annika Auranen¹⁵⁶, Airi Jussila¹³², Hannele Uusitalo-Järvinen¹⁵⁶, Hannu Kankaanranta¹⁵⁶, Hannu Uusitalo¹⁵⁶, Jukka Peltola¹⁵⁶, Mika Kähönen¹⁵⁶, Pia Isomäki¹⁵⁶, Tarja Laitinen¹⁵⁶, Tea Salmi¹⁵⁶, Anthony Muslin¹⁵⁷, Clarence Wang¹⁵⁷, Clement Chatelain¹⁵⁷, Ethan Xu¹⁵⁷, Franck Auge¹⁵⁷, Kathy Call¹⁵⁷, Kathy Klinger¹⁵⁷, Marika Crohns¹⁵⁷, Matthias Gossel¹⁵⁷, Kimmo Palin¹⁵⁸, Manuel Rivas¹⁵⁹, Harri Siirtola¹⁶⁰ & Javier Gracia Tabuenca¹⁶⁰

¹³²Pfizer, New York, NY, USA. ¹³³Finnish Institute for Health and Welfare, Helsinki, Finland. ¹³⁴THL Biobank, Finnish Institute for Health and Welfare, Helsinki, Finland. ¹³⁵Abbvie, Chicago, IL, USA. ¹³⁶Astra Zeneca, Cambridge, UK. ¹³⁷Auria Biobank, Univ. of Turku, Hospital District of Southwest Finland, Turku, Finland. ¹³⁸Biobank of Eastern Finland, University of Eastern Finland, Northern Savo Hospital District, Kuopio, Finland. ¹³⁹Biogen, Cambridge, MA, USA. ¹⁴⁰Broad Institute, Cambridge, MA, USA. ¹⁴¹Business Finland, Helsinki, Finland. ¹⁴²Celgene, Summit, NJ, USA. ¹⁴³Central Finland Biobank, University of Jyväskylä, Central Finland Health Care District, Jyväskylä, Finland. ¹⁴⁴Finnish Clinical Biobank Tampere, University of Tampere, Pirkanmaa Hospital District, Tampere, Finland. ¹⁴⁵Finnish Red Cross Blood Service, Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland. ¹⁴⁶Genentech, San Francisco, CA, USA. ¹⁴⁷GlaxoSmithKline, Brentford, UK. ¹⁴⁸Helsinki Biobank, Helsinki, Finland. ¹⁴⁹HiLIFE, University of Helsinki, Helsinki, Finland. ¹⁵⁰Hospital District of Helsinki and Uusimaa, Helsinki, Finland. ¹⁵¹Hospital District of Southwest Finland, Turku, Finland. ¹⁵²Merck, Kenilworth, NJ, USA. ¹⁵³Northern Finland Biobank Borealis, University of Oulu, Northern Ostrobothnia Hospital District, Oulu, Finland. ¹⁵⁴Northern Ostrobothnia Hospital District, Oulu, Finland. ¹⁵⁵Northern Savo Hospital District, Kuopio, Finland. ¹⁵⁶Pirkanmaa Hospital District, Tampere, Finland. ¹⁵⁷Sanofi, Paris, France. ¹⁵⁸University of Helsinki, Helsinki, Finland. ¹⁵⁹University of Stanford, Stanford, CA, USA. ¹⁶⁰University of Tampere, Tampere, Finland.

UK Biobank Eye and Vision Consortium

Tariq Aslam¹⁶¹, Sarah Barman¹⁶², Jenny Barrett¹⁶³, Paul Bishop¹⁶¹, Catey Bunce¹⁶⁴, Roxana Carare¹⁶⁵, Usha Chakravarthy¹⁶⁶, Michelle Chan¹⁶⁷, Valentina Cipriani¹⁶⁸, Alexander Day¹⁶⁷, Parul Desai¹⁶⁷, Bal Dhillon¹⁶⁹, Andrew Dick¹⁷⁰, Cathy Egan¹⁶⁷, Sarah Ennis¹⁶⁵, Paul Foster⁵⁴, Marcus Fruttiger¹⁶⁸, John Gallacher¹⁷¹,

David Garway-Heath¹⁶⁸, Jane Gibson¹⁶⁵, Dan Gore¹⁶⁷, Jeremy Guggenheim¹⁷², Chris Hammond³, Alison Hardcastle¹⁶⁸, Simon Harding¹⁷³, Ruth Hogg¹⁷⁴, Pirro Hysi^{3,190} & Pearse A. Keane¹⁶⁸, Peng T. Khaw⁵⁴, Anthony Khawaja⁴, Gerassimos Lascaratos¹⁶⁷, Andrew J. Lotery²⁸, Phil Luthert¹⁶⁸, Tom Macgillivray¹⁶⁹, Sarah Mackie¹⁶³, Bernadette Mcguinness¹⁷⁴, Gareth McKay¹⁷⁴, Martin Mckibbin¹⁷⁵, Danny Mitry¹⁶⁹, Tony Moore¹⁶⁸, James Morgan¹⁷², Zaynah Muthy¹⁶⁸, Eoin O'Sullivan¹⁷⁶, Chris Owen¹⁷⁷, Praveen Patel¹⁶⁷, Euan Paterson¹⁷⁴, Tunde Peto¹⁷⁴, Axel Petzold¹⁷⁸, Jugnoo Rahi¹⁷⁹, Alicja Rudnicka¹⁷⁷, Jay Self¹⁶⁵, Sobha Sivaprasad¹⁶⁷, David Steel¹⁶⁷, Irene Stratton¹⁸⁰, Nicholas Strouthidis¹⁶⁷, Cathie Sudlow¹⁶⁹, Caroline Thaug¹⁶⁸, Dhanes Thomas¹⁶⁷, Emanuele Trucco¹⁸¹, Adnan Tufail¹⁶⁷, Veronique Vitart¹⁹, Stephen Vernon¹⁸², Ananth Viswanathan¹⁶⁷, Cathy Williams¹⁷⁰, Katie Williams¹⁸³, Jayne Woodside¹⁷⁴, Max Yates¹⁸⁴, Jennifer Yip¹⁸⁵, Yalin Zheng¹⁷³, Robyn Tapp¹⁷⁷, Denize Atan¹⁷⁰, Alexander Doney¹⁸¹, Naomi allen¹⁷¹, Thomas Littlejohns¹⁷¹, Panagiotis Sergouniotis¹⁸⁶ & Graeme Black¹⁸⁶

¹⁶¹Manchester University, Manchester, UK. ¹⁶²Kingston University, Kingston, UK. ¹⁶³University of Leeds, Leeds, UK. ¹⁶⁴King's College London, London, UK. ¹⁶⁵University of Southampton, Southampton, UK. ¹⁶⁶Queens University, Belfast, UK. ¹⁶⁷Moorfields Eye Hospital, London, UK. ¹⁶⁸UCL Institute of Ophthalmology, London, UK. ¹⁶⁹University of Edinburgh, Edinburgh, UK. ¹⁷⁰University of Bristol, Bristol, UK. ¹⁷¹University of Oxford, Oxford, UK. ¹⁷²Cardiff University, Cardiff, UK. ¹⁷³University of Liverpool, Liverpool, UK. ¹⁷⁴Queen's University, Belfast, UK. ¹⁷⁵Leeds Teaching Hospitals NHS Trust, Leeds, UK. ¹⁷⁶King's College Hospital, London, UK. ¹⁷⁷St George's, University of London, London, UK. ¹⁷⁸UCL Institute of Neurology, London, UK. ¹⁷⁹UCL Institute of Child Health, London, UK. ¹⁸⁰Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK. ¹⁸¹University of Dundee, Dundee, UK. ¹⁸²University Hospital, Nottingham, UK. ¹⁸³King's College London, London, UK. ¹⁸⁴University of East Anglia, Norwich, UK. ¹⁸⁵University of Cambridge, Cambridge, UK. ¹⁸⁶The University of Manchester, Manchester, UK.

GIGA study group

Neema Kanyaro¹⁸⁷, Cyprian Ntomoka¹⁸⁸, Julius J. Massaga¹⁸⁹ & Joyce K. Ikungura¹⁸⁹

¹⁸⁷Department of Ophthalmology Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. ¹⁸⁸Department of Ophthalmology, Comprehensive Community Based Rehabilitation in Tanzania (CCBRT) Hospital, Dar Es Salaam, Tanzania. ¹⁸⁹National Institute for Medical Research (NIMR), Dar es Salaam, Tanzania.

23 and Me Research Team

Michelle Agee⁴⁵, Stella Aslibekyan⁴⁵, Robert K. Bell⁴⁵, Katarzyna Bryc⁴⁵, Sarah K. Clark⁴⁵, Sarah L. Elson⁴⁵, Kipper Fletez-Brant⁴⁵, Pierre Fontanillas⁴⁵, Nicholas A. Furlotte⁴⁵, Pooja M. Gandhi⁴⁵, Karl Heilbron⁴⁵, Barry Hicks⁴⁵, David A. Hinds⁴⁵, Karen E. Huber⁴⁵, Ethan M. Jewett⁴⁵, Yunxuan Jiang⁴⁵, Aaron Kleinman⁴⁵, Keng-Han Lin⁴⁵, Nadia K. Litterman⁴⁵, Jennifer C. McCreight⁴⁵, Matthew H. McIntyre⁴⁵, Kimberly F. McManus⁴⁵, Joanna L. Mountain⁴⁵, Sahar V. Mozaffari⁴⁵, Priyanka Nandakumar⁴⁵, Elizabeth S. Noblin⁴⁵, Carrie A. M. Northover⁴⁵, Jared O'Connell⁴⁵, Steven J. Pitts⁴⁵, G. David Poznik⁴⁵, J. Fah Sathirapongsasuti⁴⁵, Anjali J. Shastri⁴⁵, Janie F. Shelton⁴⁵, Suyash Shringarpure⁴⁵, Chao Tian⁴⁵, Joyce Y. Tung⁴⁵, Robert J. Tunney⁴⁵, Vladimir Vacic⁴⁵ & Amir S. Zare⁴⁵